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Interorgan communication mediated by secreted proteins is often disrupted in 
obesity, leading to insulin resistance, dyslipidemia, and cardiovascular disease. 
To further our understanding of the complex systems that regulate metabolic 
homeostasis, we investigated the biochemical and physiological properties of 
three secreted proteins. In our first two studies, we elucidated the role of 
posttranslational modifications (PTMs) in regulating the expression of two 
members of the C1q/TNF-Related Protein (CTRP) family. CTRP12 is a secreted 
regulator of glucose and lipid metabolism, and circulates in plasma as two 
distinct isoforms—a full-length protein and a cleaved, globular isoform—each of 
which preferentially activates different signaling pathways. We demonstrated that 
N-linked glycosylation found on one of three conserved asparagine residues 
regulates CTRP12 cleavage and stability. When N-linked glycosylation was 
inhibited by tunicamycin, glucosamine supplementation, or by mutation of the 
asparagine residue to glutamine, CTRP12 cleavage was enhanced. Lastly, 
cycloheximide chase analysis indicated reduced protein stability for under-
glycosylated CTRP12. We next explored how PTMs impact secretion and 
multimerization of CTRP15, a secreted glycoprotein with metabolic function. We 
showed that abolishing N-linked glycosylation by tunicamycin, glucosamine 
supplementation, or asparagine to glutamine substitutions blocks myonectin 
secretion. Of CTRP15’s four conserved cysteines, alanine substitution of either 
Cys-273 and Cys-278 inhibits protein secretion, while alanine substitutions of 
Cys-142 and Cys-194 markedly enhanced protein secretion. Formation of higher-
 
 iii 
order structures via inter-molecular disulfide bonds critically depends on Cys-142 
and Cys-194, as C142A and C194A mutations disrupted formation of high 
molecular weight oligomers. Finally, secretion of mutant lacking the highly 
hydroxylated collagen domain is strikingly reduced. In our final study, we 
describe the function of PRADC1, an enigmatic secretory protein widely 
expressed in humans and mice. Obese PRADC1-deficient female mice have 
reduced weight gain and adiposity due to increased metabolic rate, physical 
activity, and energy expenditure, but do not show improved systemic glucose and 
lipid metabolism. Thus, in PRADC1-deficient animals, decreased fat mass and 
enhanced physical activity are insufficient to confer a healthy metabolic 
phenotype in the context of an obesogenic diet. Taken together, our studies 
highlight novel functions of posttranslational modifications and a secreted protein 
in regulating systemic energy homeostasis. 
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Secreted proteins play a critical role in maintaining proper energy balance 
in mammals. These proteins are dynamically regulated and mediate inter-organ 
crosstalk between tissues in order to coordinate responses to metabolic stress. 
Regulation of these hormones is often disrupted in the context of obesity, leading 
to insulin resistance, type 2 diabetes, dyslipidemia, and cardiovascular diseases  
(1–4) . 
Our ability to prevent, treat, and cure these metabolic diseases is impeded 
by our incomplete understanding of the complex metabolic pathways that work to 
maintain glucose and lipid homeostasis. To address this challenge, we have 
characterized a highly conserved family of secreted proteins based on their 
homology to adiponectin, an adipose-derived anti-diabetic hormone. First 
described in 2004 (5) , the members of this protein family, designated C1q/TNF-
Related Proteins (CTRP) 1-15, share the same domain structure as adiponectin. 
With the exception of CTRP4 (6) , each protein consists of an N-terminal domain 
with a signal peptide that promotes secretion, a collagen domain containing 
multiple Gly-X-Y repeats, and a C1q domain that is homologous to the C1q 
complement protein and structurally similar to TNF- (7) .  
CTRPs are collectively expressed in a wide range of tissues. Most are found 
circulating in plasma, and their levels change with the metabolic and nutritional 
state of an animal. Several functional studies have demonstrated important roles 
for CTRPs in metabolism (6, 8–16) , immunology (17–19) , the cardiovascular 
system, (20–26)  ophthalmology (27–32) , and pulmonary physiology (33) . All 
CTRPs form trimers, mediated by disulfide bonds formed between conserved 
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cysteine residues found within their N-terminal domains (34) . Many also form 
higher order homo- and hetero- oligomers with adiponectin and other CTRPs (34–
38) . In addition to disulfide bonds that enable multimerization, CTRPs contain 
various post-translational modifications (PTMs), including glycosylation and 
hydroxylation (34) . It is well understood that PTMs found on adiponectin are critical 
for the hormone’s oligomerization (39–41) , stability (42, 43) , and secretion (40, 
44, 45) . Furthermore, adiponectin’s biological activity varies with its PTM and 
oligomeric state (46–48) , and disrupted ratios of circulating adiponectin oligomers 
are associated with obesity and type 2 diabetes (49–59) . 
Despite clear ties between adiponectin PTMs and the hormone’s bioactivity, 
the significance of PTMs in regulating CTRP expression, processing, and function 
remains largely unexplored. Given the important role CTRPs play in maintaining 
whole-body energy homeostasis, we sought to determine how various PTMs, 
including N-linked glycosylation, disulfide bonds, and hydroxylation, influence the 
expression, multimerization, and function of CTRPs. The following work focuses 
on PTM regulation of two members of this family, CTRP12 and CTRP15. In 
addition, we have also characterized a novel, metabolic-responsive secreted 
glycoprotein, PRADC1, in order to further our understanding of how secreted 








CTRP12 as a regulator of glucose metabolism and insulin sensitivity 
CTRP12, also known as adipolin, is an antidiabetic, adipose-derived secreted 
protein that regulates glucose and lipid metabolism. Its expression is responsive 
to insulin. In cultured 3T3-L1 adipocytes, CTRP12 expression increased following 
insulin supplementation in a dose-dependent manner  (60) . Insulin infusion in 
healthy, lean human subjects also increases circulating CTRP12 levels (61) . 
Treating cultured adipocytes, human adipose tissue explants, or human subjects 
with the insulin-sensitizing drugs rosiglitazone and metformin similarly increased 
CTRP12 transcript and protein levels (60–64) . These effects appear to be 
mediated by activation of AMPK, a key downstream target of insulin signaling, as 
treating human adipose tissue explants with an AMPK inhibitor blocks this increase 
in expression (63) . In both genetic and diet-induced mouse models of obesity, and 
in patients with type 2 diabetes, CTRP12 expression is decreased (60, 62, 65, 66) 
, suggesting that CTRP12 may be a useful biomarker for the prediction and early 
diagnosis of type 2 diabetes (66) . Taken together, these results illustrate the role 
of insulin signaling in regulating CTRP12 expression, and demonstrate that this 
regulation may be disrupted by obesity.  
Once expressed and secreted into the bloodstream, CTRP12 improves 
glucose handling and insulin sensitivity. Increasing circulating CTRP12 levels 
through either acute adenovirus-mediated overexpression or by administering 
recombinant CTRP12 leads to reduced serum glucose and insulin levels in lean 
and obese mice (60, 62) . These mice also show improved insulin sensitivity, 
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demonstrated by faster glucose clearance from serum following injection with a 
bolus of glucose, lower post-prandial insulin levels, and a reduced homeostatic 
model assessment-insulin resistance (HOMA-IR) index. CTRP12 promotes 
glucose uptake in response to insulin by enhancing signaling through the PI3K-Akt 
pathway. In the livers and adipose tissue of both healthy and insulin-resistant mice, 
CTRP12 overexpression increased activation of critical insulin signaling 
molecules; phosphorylation of insulin receptor substrate (IRS-1) and Akt increased 
significantly in response to CTRP12 overexpression (60) . Enhanced Akt 
phosphorylation, along with phosphorylation of FOXO-1 and suppression of 
gluconeogenic genes PEPCK and G6Pase, was also observed in cultured 
hepatocytes and adipocytes. Use of a PI3K-specific inhibitor abolished these 
effects (60) . No changes in PI3K-Akt signaling were observed in the skeletal 
muscle of mice overexpressing CTRP12, or in cultured L6 myotubes. These results 
illustrate how CTRP12 acts as an anti-diabetic hormone by improving insulin 
sensitivity in liver and adipose tissue, and demonstrate its potential as a 
therapeutic for insulin resistance. 
 
CTRP12 and lipid metabolism 
Given the impact of obesity on CTRP12 expression we sought to determine 
whether CTRP12 plays a role in whole body lipid metabolism. Whereas Enomoto 
et al., reported reduced adipocyte size and suppression of pro-inflammatory genes 
in cultured mouse macrophages in a CTRP12 overexpression model (62) , our 
group observed no influence of CTRP12 overexpression on adipocyte size or 
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adipose tissue inflammation in mice (60) . Interestingly, while overexpression did 
not modulate serum fatty acid or triglyceride levels (60, 62) , CTRP12 deficiency 
led to altered lipid homeostasis. In a heterozygous loss-of-function mouse model, 
losing one copy of CTRP12 resulted in increased hepatic fat oxidation and reduced 
VLDL-triglyceride secretion from the liver in male mice fed a low-fat diet (67) . 
Conversely, in the context of metabolic stress induced by high-fat feeding, 
CTRP12-deficient mice showed impaired lipid handling; serum fatty acid and 
triglyceride levels remained significantly higher that wildtype littermates after mice 
were gavaged with a bolus of emulsified lipid (67) . Elevated hepatic triglyceride 
and cholesterol levels accompanied by reduced hepatic triglyceride secretion in 
CTRP12-deficient mice resulted in greater liver steatosis than in wildtype 
littermates, suggesting that CTRP12 promotes mobilization of lipids from the liver 
(67) . These results differed from those seen in heterozygous female mice, which 
were indistinguishable from wildtype littermates on a low-fat diet, and showed 
enhanced hepatic triglyceride secretion and mild insulin resistance on a high-fat 
diet (67) . Taken together, these observations highlight the complexity of the 
components that regulate lipid homeostasis, and illustrate how these systems may 
be differentially disrupted in males and females in the context of obesity. 
 
CTRP12 cleavage 
Prior to secretion, CTRP12 is cleaved by furin proprotein convertase within the N-
terminal domain, forming a cleaved, globular isoform (65, 68) . Both the globular 
(gCTRP12) and full-length (fCTRP12) isoforms are secreted (60) , and the ratio of 
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globular to full-length CTRP12 is disrupted in obesity (65) . In diet-induced obese 
mice, the proportion of gCTRP12 relative to fCTRP12 is increased (65) , indicating 
that proteolytic processing of the protein is regulated. Additionally, each isoform 
appears to have distinct functions. Although insulin treatment increases overall 
CTRP12 expression in cells (60) , this impact appears to be primarily driven by 
increased gCTRP12 expression, rather than by fCTRP12 (68) . Furthermore, each 
isoform activates distinct signaling pathways. In cultured hepatocytes and 
adipocytes, fCTRP12 treatment enhances IRS-1 and Akt phosphorylation, while 
gCTRP12 preferentially activates the MAPK signaling pathway (68) . Collectively, 
these results suggest that regulating CTRP12 cleavage may in turn regulate its 
function as an anti-diabetic hormone. Given CTRP12’s important role as a 
regulator of glucose metabolism and insulin sensitivity, more work must be done 
to elucidate how this cleavage is controlled and dysregulated in the context of 
obesity. Chapter 2 describes my study investigating the role of N-linked 
glycosylation in regulating CTRP12 cleavage.  
 
CTRP12 and cardiovascular disease 
In addition to its involvement in maintaining whole body lipid and glucose 
homeostasis, CTRP12 is also implicated in cardiovascular disease. Patients with 
coronary artery disease showed significantly reduced serum CTRP12 levels, 
independent of body mass index and insulin resistance parameters (69) . Mice 
deficient in CTRP12 show worse recovery outcomes following vascular injury to 
the femoral artery, results that are mediated by the macrophage inflammatory 
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response (70) . In another study, Zhou et al developed an in vitro cardiomyocyte 
injury system, in which cardiomyocytes were treated with lipopolysaccharide (LPS) 
to model sepsis-induced cardiac injury (71) . CTRP12 overexpression suppressed 
hyperinflammation, reduced oxidative stress, and mitigated LPS-induced 
apoptosis, resulting in improved cardiomyocyte viability (71) . The study suggests 
that CTRP12 acts by increasing expression of nuclear factor E2-related factor 2 
(NRF2), an antioxidant-responsive transcription factor that mitigates oxidative 
stress, though this mechanism of CTRP12 action has yet to be further explored. 
Collectively, these results demonstrate the cardioprotective properties of CTRP12. 
 
In summary, CTRP12 is a secreted adipokine with anti-diabetic and anti-
inflammatory properties. Several questions remain about the protein’s structure 
and physiological roles in metabolism and cardiovascular health. Like all members 
of the CTRP family, no known CTRP12 receptor has been identified, precluding a 
complete understanding of the mechanisms underlying its physiology. With 
respect to protein structure, future studies should explore how differential N-linked 
glycosylation impacts CTRP12 bioactivity. Furthermore, more work must be done 
to elucidate the protein’s specific role in the prevention of coronary artery disease 








Myonectin as a regulator of whole-body lipid homeostasis 
CTRP15, also termed myonectin, is expressed and secreted predominantly by the 
skeletal muscle, and mediates inter-organ crosstalk between three key metabolic 
tissues—skeletal muscle, liver, and adipose tissue. Myonectin expression is highly 
responsive to metabolic state, as demonstrated by both in vitro and in vivo 
experiments. Treating cultured myotubes with glucose, amino acids, or fatty acids 
stimulates myonectin expression (8) . Levels of circulating myonectin increase 
dramatically in response to exercise or feeding, while fasting reduces its 
expression (8) . In line with these observations, increasing intracellular cAMP or 
calcium levels in cultured myotubes via treatment with forskolin, epinephrine, or 
ionomycin also increases myonectin expression. These results suggest that acute 
fluctuations in nutritional state are sufficient to alter myonectin expression. Once 
produced, circulating myonectin works post-prandially to increase fatty acid uptake 
in peripheral tissues by upregulating transcription of proteins critical for fatty acid 
transport into cells (Cav1, Fabp1, CD36, and Fabp4) (8) . In response to infusion 
with recombinant myonectin, serum levels of non-esterified fatty acid (NEFA) in 
wildtype mice drop significantly. Similarly, in the context of metabolic stress 
induced by high fat feeding, myonectin-deficient mice show elevated NEFA and 
triglyceride levels in serum following an oral lipid gavage. These mice also show 
altered lipid storage in peripheral tissues, with reduced hepatic lipid content and 
larger adipose tissue depots (72) . These observations suggest that myonectin 
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stimulates lipid clearance in a tissue-specific manner, and plays a role in regulating 
lipid distribution among tissues. 
While several studies associate insulin resistance and obesity with 
decreased myonectin expression (8, 73) , a few studies show an increase in 
myonectin expression in patients with type 2 diabetes (74–76) ,  suggesting a 
compensatory role for the protein. Thus, further studies must be performed to 
determine whether myonectin expression is dysregulated and contributes to insulin 
resistance, or if expression increases to compensate for metabolic dysfunction. 
Nonetheless, these findings collectively highlight myonectin’s function as a 
nutrient-responsive myokine that integrates skeletal muscle, liver, and adipose 
tissue lipid metabolism.  
 
Myonectin and exercise 
In addition to fluxes in glucose and lipid levels, myonectin expression is also 
induced by exercise (8, 77–79) . Both acute (8, 77)  and chronic (78)  exercise 
result in elevated myonectin expression in mouse serum and skeletal muscle, 
respectively. These results have been recapitulated in humans. When obese 
women were subjected to eight weeks of aerobic exercise, their circulating 
myonectin levels increased significantly (79) , indicating a correlation between 
elevated myonectin levels and improved metabolic parameters associated with 
exercise. However, how myonectin contributes to these improved outcomes has 
yet to be determined. In a knockout mouse model, in response to either maximal 
sprint or endurance exercise on a treadmill, myonectin-deficient mice showed no 
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differences in total running distance, no changes in the post-exercise serum levels 
of glucose, lactate, NEFA, triglyceride, and ketone, and no changes in ability to 
replenish glycogen stores in their skeletal muscle or liver (72) . Taken together, 
these results suggest that although myonectin is not required for the improved 
metabolic response associated with exercise, it may play a role in regulating fatty 
acid metabolism within skeletal muscle,  
Conversely, another group has demonstrated that changes in myonectin 
expression may directly contribute to the cardioprotective benefits of exercise. 
Otaka et al. found that myonectin acts to improve acute myocardial ischemic injury 
outcomes. In wildtype mice with exercise-induced, elevated myonectin expression, 
and in transgenic mice overexpressing myonectin, ischemia reperfusion injury 
resulted in reduced myocardial infarct size and cardiac dysfunction. 
Comparatively, myonectin-knockout mice showed worse cardiac outcomes (77) . 
In cultured myocytes, the authors found that myonectin inhibits apoptosis and 
reduces proinflammatory gene expression, suggesting a mechanism for these 
outcomes. This finding is in line with a previous study describing myonectin’s role 
in suppressing autophagy in mouse liver and cultured hepatocytes (16) . 
 
Myonectin and iron metabolism 
Since we first identified myonectin/CTRP15 in 2012, it has also been described as 
erythroferrone, as it is secreted from erythroblasts and regulates iron metabolism 
following significant blood loss (80) . In response to stress erythropoiesis, 
myonectin/erythroferrone acts to mobilize iron stores from the liver and spleen by 
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suppressing expression of hepcidin, a liver-derived hormone that inhibits the 
cellular iron exporter ferroportin (81) . While several studies have demonstrated a 
link between imbalances in iron homeostasis and the development of diabetes 
(82–88) , the role myonectin plays in this observation has yet to be explored.  
 
Despite extensive research on CTRP15, more work must be done to fully 
elucidate its role in nutrient metabolism, exercise physiology, and iron metabolism. 
Whether myonectin contributes, directly or indirectly, to improved metabolic 
outcomes associated with exercise is of particular interest. In addition, the 
mechanisms underlying myonectin’s tissue-specific regulation of fat metabolism 
remain unknown. Finally, a complete understanding of how myonectin bioactivity 




Chapter 4 details a study on protease-associated domain-containing 1 (PRADC1), 
an enigmatic secreted glycoprotein that was first identified in 2004 (89) . Two 
genetics studies have associated the Pradc1 gene with metabolism (90)  and 
familial colorectal cancer (91) . Nonetheless, very little is known of this protein’s 
function. Also known as protease-associated domain-containing protein, 21 kDa  
(PAP21), it is highly expressed in metabolic-responsive tissues (skeletal muscle, 
heart, and liver), and requires N-linked glycosylation for secretion (89) . Given this 
striking expression pattern, we hypothesized that PRADC1 is involved in regulating 
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whole-body energy homeostasis, and responds to changes in metabolic state. 
However, what role this novel secreted protein plays in regulating energy 
metabolism has not been explored. Thus, in Chapter 4, we describe the first 
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C1q/TNF-related protein 12 (CTRP12) is a secreted regulator of glucose and lipid 
metabolism. It circulates in plasma as a full-length protein or as a cleaved isoform 
generated by furin/PCSK3 cleavage. These isoforms preferentially activate 
different signaling pathways and their ratio in plasma is altered in obesity and 
diabetes. Here, we show that three conserved asparagine residues (Asn-39, Asn-
287, and Asn-297) play important roles in modulating CTRP12 cleavage, 
secretion, and stability. Mass spectrometry analysis provided direct evidence of 
Asn-39 glycosylation. When N-linked glycosylation was inhibited by tunicamycin or 
abolished by N39Q, N39A, or T41A mutation, CTRP12 cleavage was enhanced. 
Complex-type N-glycans on CTRP12 blocked cleavage by the Golgi-localized 
furin. In N-acetyl glucosaminyltransferase I (GnTI)-deficient cells that could not 
form hybrid and complex-type N-glycans in the Golgi, CTRP12 cleavage was 
enhanced, and re-expressing GnTI reduced cleavage. Replacing the non-
glycosylated Asn-297 with glutamine or alanine also increased CTRP12 cleavage. 
Both Asn-39 and Asn-297 contributed independently to CTRP12 cleavage: 
maximum cleavage was observed in the double mutant. Further, CTRP12 
cleavage was abolished in furin-deficient cells and restored by furin re-expression. 
Replacing the non-glycosylated Asn-287 with glutamine or alanine resulted in 
protein misfolding and aggregation, leading to retention in the endoplasmic 
reticulum. Cycloheximide chase analyses indicated reduced protein stability for 
N39Q, T41A, and N297Q mutants. Lastly, we show that increasing flux through 
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the hexosamine biosynthesis pathway by exogenous glucosamine, known to 
disrupt protein glycosylation, also promoted CTRP12 cleavage. Combined, these 
data highlight glycosylation-dependent and independent mechanisms regulating 




CTRPs are a conserved family of secreted plasma proteins (1-9). They 
belong to the larger C1q family of proteins and each possesses the signature C-
terminal globular domain homologous to immune complement C1q (10,11). 
Recent in vivo studies using recombinant protein supplementation or transgenic 
and knockout mouse models have revealed important functions for multiple CTRP 
family members in modulating insulin action and glucose and lipid metabolism 
(7,8,12-23).  
We identified CTRP12 (encoded by the C1QTNF12 gene) on the basis of 
shared sequence homology with other previously characterized CTRP family 
members (4,24). Independently, Enomoto et al. also identified CTRP12/adipolin as 
an adipose-enriched transcript that encodes a novel adipokine (25). CTRP12 
expression in mice is modulated by metabolic and physiological states and its 
transcript level is downregulated in obesity and diabetes (4,25) and upregulated in 
the context of enhanced insulin sensitivity (26). Insulin infusion in healthy lean 
humans can acutely increase plasma CTRP12 levels (27). Treatment with anti-
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diabetic drugs (e.g., rosiglitazone and metformin) also increases the expression 
and secretion of CTRP12 in human adipose tissue (27-29).  
Using recombinant protein infusion and adenoviral overexpression 
approaches, we and others have demonstrated an anti-diabetic (4) and anti-
inflammatory (25) function for CTRP12 in both genetic (ob/ob) and dietary (high-
fat feeding) mouse models of obesity and diabetes. CTRP12 regulates glucose 
metabolism in liver and adipose tissue through insulin-dependent and independent 
pathways (4). Partial deficiency of CTRP12, resulting from targeted inactivation of 
a single copy of the Ctrp12 allele in mice, alters lipid metabolism in liver in a sex-
dependent manner (30). 
CTRP12 that circulates in plasma and is secreted from adipocytes exists in 
two natural isoforms. Proteolytic cleavage at the conserved Lys-91 by the 
proprotein convertase furin/PCSK3 in the Golgi generates a shorter globular 
gCTRP12 isoform (24). Circulating levels of the cleaved gCTRP12 isoform, relative 
to the full-length protein, are increased in diet-induced obese and insulin resistant 
mouse models (31). In cultured 3T3-L1 adipocytes, insulin treatment also 
promotes the expression and generation of cleaved gCTRP12 (24). The full-length 
protein (trimer) and globular gCTRP12 (dimer) differ in their oligomeric state. The 
full-length protein and gCTRP12 isoforms appear to preferentially activate the Akt 
and MAPK signaling pathways, respectively, in cultured hepatocyte and adipocyte 
cell lines (24) suggesting that they may have both overlapping and distinct 
functions. What regulates the secretion and proteolytic cleavage of CTRP12, 
however, is unknown. In the present study, we reveal the importance of the three 
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conserved asparagine residues (Asn-39, Asn-287, and Asn-297) in modulating 
protein secretion and the extent of proteolytic cleavage by furin/PCSK3 
endopeptidase. Our data also provides a novel function for N-linked glycosylation 
in modulating protein cleavage by proprotein convertases within the secretory 
pathway.   
 
 
Materials and Methods 
 
Materials 
Tris(2-carboxyethyl)phosphine (TCEP) was obtained from Thermo Scientific 
(Rockford, IL). Iodoacetamide, tunicamycin, glucosamine, and mouse monoclonal 
anti-FLAG M2 antibody were obtained from Sigma-Aldrich (St. Louis, MO). Rabbit 
polyclonal anti-human GntI/MGAT1 antibody (15103-1-AP) was obtained from 
Proteintech. Mouse monoclonal anti-CHOP (9C8; MA1-250) was obtained from 
Thermo Fisher Scientific. Rabbit anti-human/mouse XBP-1 antibody was obtained 
from Abcam (ab37152). Rabbit monoclonal antibodies against spliced XBP-1s 
(D2C1F) and ATF-6 (D4Z8V) were obtained from Cell Signaling Technology. 
Trypsin and chymotrypsin were purchased from Promega (Madison, WI), 
hydrazine resin was from Bio-Rad (Hercules, CA) and PNGase F and 
Endoglycosidase H (Endo H) were from New England Biolabs (Ipswich, MA). 
Furin/PCSK3 inhibitor was obtained from Cayman Chemical. The furin/PCSK3 
inhibitor (decanoyl-Arg-Val-Lys-Arg-CMK) was obtained from Cayman Chemical 
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(catalog # 14965). Cycloheximide was purchased from Calbiochem (catalog # 
239764). 
 
Protein digestion and N-linked glycopeptide enrichment 
To aid protein digestion by proteases, urea was added to 25 μg of protein samples 
in 25 mM HEPES, 135 mM NaCl, pH 8 to a final concentration of 8 M. Protein was 
reduced and alkylated with 10 mM TCEP and 15 mM iodoacetamide, respectively. 
Urea concentration was reduced with 50 mM triethylammonium bicarbonate to a 
final concentration of 1 M and subjected to serial digestion with trypsin (1:25 
enzyme-protein ratio) and chymotrypsin (1:25 enzyme-protein ratio) at 37°C 
overnight. Glycosylated peptides were enriched using solid-phase extraction of N-
linked glycoprotein (SPEG) as previously described with minor modifications (32). 
Briefly, peptides were subjected to C18 Stage Tip clean-up (33), oxidized with 10 
mM sodium periodate, and incubated at room temperature for 1 hour.  Peptides 
were desalted using C18 Stage Tip prior to conjugation to hydrazide resin via 
overnight coupling in 80% acetonitrile, 0.1% TFA (trifluoroacetic acid), and 1% 
aniline.  Non-glycosylated peptides were removed by washing the resin three times 
each with 1 mL of 50% acetonitrile, 1.5 M NaCl, HPLC-H2O, and 25 mM 
triethylammonium bicarbonate.  N-linked glycosite-containing peptides were 
released from the resin by incubation overnight with 3 μL of PNGase F in 25 mM 
triethylammonium bicarbonate. Released glycosite-containing peptides were 
collected after centrifugation at 3,000 x g. The resin was then rinsed with 50% 
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acetonitrile twice and pooled.  The peptide solution was desalted, dried, and 
reconstituted in 0.1% formic acid and subjected to MS analysis. 
 
LC-MS/MS analysis and protein identification 
Peptides were analyzed via ESI-LC-MS/MS as previously described (34). N-linked 
glycosite-containing peptides (~1 μg) were separated through a Dionex Ultimate 
3000 RSLC nano system (Thermo Scientific) with a 75 μm x 15 cm Acclaim 
PepMap100 separating column (Thermo Scientific) protected by a 2 cm guard 
column (Thermo Scientific). The mobile phase consisted of 0.1% formic acid in 
water (A) and 0.1% formic acid/95% acetonitrile (B). Flow rate was 300 nl/min, with 
a gradient profile as follows: 4-35% B for 70 min, 35-95% B for 5 min, 95% B for 
10 min, and equilibrated in 4% B for 15 min. MS analysis was performed using an 
Orbitrap Velos Pro mass spectrometer (Thermo Scientific). The spray voltage was 
set at 2.2 kV. Orbitrap spectra (AGC 1x106) were collected from 400-1800 m/z at 
a resolution of 60K followed by data-dependent HCD MS/MS (at a resolution of 
7500, collision energy 35%, activation time 0.1 ms) of the ten most abundance 
ions using an isolation width of 2.0 Da. Charge state screening was enabled to 
reject unassigned and singly charged ions. A dynamic exclusion time of 35 sec 
was used to discriminate against previously selected ions. Peptides were identified 
using Proteome Discoverer software (Thermo Scientific, ver 1.3). Spectra were 
searched against the CTRP12/Adipolin protein sequence [UniProtKB – Q8R2Z0, 
ADIPL_MOUSE)]. The precursor mass tolerance was set at 20 ppm and the 
MS/MS tolerance at 0.06 Da. Parameters of the search included: variable 
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modifications such as methionine oxidation (+15.99492) and asparagine 
deamidation (+0.984016); fixed modification such as cysteine 
carbamidomethylation (+57.02510); digestion enzymes such as trypsin and 
chymotrypsin, and a maximum of two missed cleavages were allowed. 
 
cDNA constructs 
All C-terminal FLAG epitope-tagged mouse CTRP12 (NCBI GenBank accession 
no. NP_080401) single, double, and triple mutant constructs (N39Q, N39A, 
N287Q, N287A, N297Q, N297A, T41A, S289A, S299A, N39Q/N287Q, 
N39Q/N297Q, N287Q/N297Q, N39Q/N287Q/N297Q) were generated by either 
site-directed mutagenesis or by GenScript. We also generated an N-terminal 
FLAG epitope-tagged version of wild-type mouse CTRP12 and the single mutants 
(N287Q and N297Q). The FLAG tag (DYKDDDDK) was inserted immediately 
downstream of the signal peptide (amino acid residue 1-22). All cDNA inserts were 
cloned into the EcoRI restriction site of the mammalian expression vector 
pCDNA3.1 (Invitrogen) and verified by DNA sequencing. Untagged human 
GnTI/MGAT1 (NM_002406) and C-terminal FLAG-tagged mouse furin/PCSK3 
(NM_001081454) expression plasmids were obtained from Origene and verified 
by sequencing.  
 
Cell culture and transfection 
GripTite™ 293 cells (Invitrogen) and GnTI-deficient HEK293S cells (ATCC; CRL-
3022) (35) were cultured in DMEM (Invitrogen) containing 10% fetal bovine serum 
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(FBS), 4 mM L-glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin. 
Transfections were carried out using Lipofectamine (Invitrogen) according to the 
manufacturer’s instructions. Twenty-four hours post transfection, medium was 
replaced with serum-free Opti-MEM (Invitrogen). Both cell lysates and media from 
transfected cells were then collected 24 h later. Cell lysates were prepared by 
solubilizing cells in whole cell extract buffer (20 mM Tris-HCL (pH 7.5), 150 mM 
NaCl, 1 mM Na2EDTA, 0.5% NP-40, 10% glycerol) containing SIGMAFASTTM 
protease inhibitor cocktail (Sigma) and phosSTOP phosphatase inhibitor cocktail 
(Roche). In our transfection studies, the experiments had been repeated 2-4 times; 
each time we performed six independent transfections on different dishes of cells. 
For tunicamycin and glucosamine treatments, GripTite™ 293 cells were cultured 
in media containing tunicamycin (0.5 μg/mL) or glucosamine (1 or 5 mM) 2 hours 
before transfection. We used the concentration of glucosamine (5 mM) known to 
disrupt N-glycosylation (36-38). Twenty-four hours post transfection, medium was 
replaced with serum-free Opti-MEM (Invitrogen). Both cell lysates and media from 
transfected cells were then collected 24 h later. In the case of furin inhibitor, cells 
were cultured in the presence of inhibitor (50 μM) from the day of transfection and 
the inhibitor remained in Opti-MEM media for another 24 hr until cell lysates were 
harvested. The dose of furin inhibitor used was based on previous studies(39,40). 
LoVo cells (CCL-229; ATCC), a human colon carcinoma cell line deficient in furin 
(41), were cultured in F-12K medium (ATCC) supplemented with 10% FBS and 
penicillin/streptomycin. Transfection of mouse furin cDNA into LoVo cells was 




Western blot analysis 
For Western blot analyses, cell lysates in loading buffer (50 mM Tris, 2% SDS, 1% 
β-ME, 6% glycerol, 0.01% bromophenol blue) were incubated at 94 °C for 5 min. 
Proteins were separated in 10% or 8-16% pre-cast mini-PROTEAN TGX gel (Bio-
Rad), immunoblotted onto nitrocellulose membrane (Bio-Rad), blocked with 5% 
non-fat milk for 1 h, and probed with mouse anti-FLAG M2 (1:1000), rabbit anti-
human MGAT1 primary antibody (1:1000), mouse anti-CHOP monoclonal 
antibody (1:1000), or rabbit anti-XBP-1 polyclonal antibody (1:1000)  overnight. 
Immunoblots were washed 3X (10 min each) in PBS containing 0.1% Tween-20 
and incubated with horseradish perioxidase-conjugated secondary antibody 
(Amersham Biosciences) (1:2000) for 1 hr. Blots were washed 3X (10 min each) 
in PBS containing 0.1% Tween 20, developed in ECL reagent (Millipore) for 2-5 
min, and visualized with MultiImage III FluorChem ® Q (Alpha Innotech). 
Quantifications of signal intensity were performed using Image J software. The 
cleavage index is defined as the ratio of cleaved globular secreted protein to full-
length isoform in the supernatant of transfected cells; this describes the extent of 
proteolytic cleavage of the secreted CTRP12. The secretion index is defined as 
the ratio of total secreted CTRP12 (full length and globular isoform) to intracellular 






We performed cycloheximide chase experiments to determine if N39Q, T41A, 
N297Q mutation, or glucosamine treatment, affect CTRP12 protein stability. 
Cycloheximide blocks new protein synthesis; this allows us to determine the rate 
of protein turnover and hence protein stability. HEK 293 cells were transfected with 
wild-type mouse CTRP12 or the indicated mutants. The following day (at t=0) cells 
were harvested. For the remaining cells, the medium was removed and replaced 
with Opti-MEM containing 100 μg/mL cycloheximide. Cells were harvested 6 hr 
after treatment and subjected to immunoblot analysis using the anti-FLAG M2 
antibody. The ratio of wild-type CTRP12 after a 6 hr cycloheximide chase to its 
control (harvested at t=0 before cycloheximide treatment) was considered 1. The 
relative turnover of different mutants were then compared to wild-type CTRP12.    
 
Glycoprotein detection 
Experiments were carried as previously described (36).  Briefly, HEK 293 cells 
were treated with 1 or 5 mM glucosamine (GlcN; G4875; Sigma) for 48 hr and 
harvested as described above. Equal amount of cell lysates were separated by 
SDS-PAGE. Gels were stained for general glycosylation of proteins using the Pro-
Q Emerald 3000 Glycoprotein gel stain kit (P21857; Thermo Scientific). To 
specifically stain for N-glycosylated proteins, proteins were transferred to 
nitrocellulose membranes,  blocked with 5% non-fat milk for 1 hour, and probed 
overnight with concanavalin A-biotin conjugate (30 μg/mL) (C2272; Sigma). 
Immunoblots were washed 3X (10 min each) in PBS containing 0.1% Tween-20 
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and incubated with horseradish perioxidase-conjugated avidin (1:20,000) 
(1706528; Bio-Rad). Blots were washed 3X (10 min each) in PBS containing 0.1% 
Tween 20, developed in ECL reagent (Millipore) for 2-5 min, and visualized with 
MultiImage III FluorChem ® Q (Alpha Innotech). Subsequently, gels and blots were 
stained for total protein using EZBlue Gel Staining Reagent (G1041; Sigma). 
Quantifications of signal intensity were performed using Image J software.  
 
RT-PCR analysis 
Total RNAs were isolated from HEK 293 cells expressing a wild-type GnTI/MGAT1 
and GnTI-deficient HEK 293S using Trizol reagent. Potential genomic DNA was 
removed by DNAase I digest. Reverse transcription was carried out using random 
primers and GoScript reverse transcriptase (Promega). The following primers were 
used to amplify the entire coding region of human GnTI/MGAT1 mRNA: forward, 
5’-CTAGGACTGCGGGCAAGGGAGCCG-3’, and reverse, 5’-
GGGCCCAGGAAGGACAGGCAGGTG-3’. PfuUltra high fedelity polymerase 
(Agilent) was used  in a 36-cycle PCR reactions: denaturing at 95°C for 30 
seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 2 min. 
Amplified PCR product was separated on 1% agarose gel, excised and purified, 








Comparisons were performed using two-tail Student’s t-tests. Values were 
considered significant at p< 0.05. All data are presented as mean ± standard error 




Inhibition of N-linked glycosylation enhances CTRP12 cleavage 
Mouse CTRP12 possess three potential N-linked glycosylation sites at Asn-39, 
Asn-287, and Asn-297 that conform to the consensus Asn-X-Ser/Thr (where X is 
any amino acid except proline) (Fig. 1A). Two of these sites (Asn-39 and Asn-287) 
are conserved in human CTRP12. At least one of these sites, Asn-39, was 
previously suggested to be glycosylated based on changes in the apparent 
molecular weight of the N39A mutant of CTRP12 relative to wild-type protein on 
immunoblot (24). N-linked glycans are known to play an important role in the 
quality control of protein folding in the endoplasmic reticulum (42). To assess the 
impact of glycosylation on CTRP12 expression, we used tunicamycin to block N-
glycosylation. This aminoglycoside antibiotic inhibits the first step in the lipid-linked 
oligosaccharide biosynthesis pathway (43,44). In heterologous HEK 293 cells 
expressing mouse CTRP12, inhibiting N-linked glycosylation did not affect protein 
expression and secretion; however, we observed significantly enhanced cleavage 






Figure 1.  Inhibition of N-glycosylation enhances CTRP12 cleavage. A, Domain 
structure of mouse CTRP12. The conserved furin-cleavage site (Lys-91) and the 
three potential N-linked glycosylation sites (Asn-39, Asn-287, and Asn-297) that 
conform to the N-X-S/T motif are indicated. The C-terminal FLAG tag is also 
indicated. B, Western blot analysis (using anti-FLAG M2 antibody) of cell lysate 
and supernatant of transfected HEK 293 cells treated with vehicle control or 
tunicamycin, an inhibitor of N-glycosylation. C, Quantification of the ratio of cleaved 
to full-length protein in the supernatant. FL, full-length; N=6 (each lane represents 
a different sample from an independent transfection); ****p<0.0001 
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Identification of N-glycans on CTRP12 using mass spectrometry 
Given that N-linked glycosylation influences the extent of CTRP12 proteolytic 
cleavage, we sought to determine whether Asn-39, Asn-287, and Asn-297 are 
indeed glycosylated. While previous assessment of N-linked glycosylation by 
PNGase F suggests the presence of glycans on Asn-39 (24), it remains unresolved 
whether Asn-287 and Asn-297 are also glycosylated. For this reason, we subjected 
purified recombinant mouse CTRP12 to mass spectrometry analysis. Using this 
method, we provided direct evidence that Asn-39 is indeed glycosylated (Fig. 2A). 
Whether Asn-287 and Asn-297 are also glycosylated could not be determined by 
mass spectrometry in the present study; the C-terminal peptide fragment 
containing Asn-287 and Asn-297 was not detected by mass spectrometry. We 
therefore used site-directed mutagenesis to assess whether Asn-287 and/or Asn-
297 are glycosylated. As expected, replacing Asn-39 with glutamine led to a 
significant shift in the apparent molecular mass of the secreted protein on 
immunoblot relative to wild-type protein (Fig. 2B). In contrast, replacing Asn-297 
with glutamine did not result in a shift of molecular mass of the secreted protein on 
immunoblot, suggesting that this site is not glycosylated. Replacing Asn-287 with 
glutamine also did not reduce the apparent molecular weight of the mutant protein 
relative to wild-type protein on immunoblot, suggesting that Asn-287 is also not 
glycosylated. To rule out whether the C-terminal FLAG epitope tag affects Asn-
287 and Asn-297 glycosylation, we also generated constructs encoding N-terminal 
FLAG tagged mouse CTRP12. The epitope tag was inserted immediately 
downstream of the signal peptide. As shown in Fig. 2C, placing the epitope tag at 
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the N-terminus did not affect the glycosylation outcome for WT, N297Q, and 
N287Q mutant (Fig. 2C). These results indicate that only Asn-39 is glycosylated.  





Figure 2.  Mass spectrometry and mutational analysis of N-glycosylation in 
CTRP12. A, MS/MS mass spectrum of the glycopeptide ARVDSPNITTSNR 
derived from CTRP12 identified using Proteome Discoverer. Higher-energy 
collisional dissociation (HCD) generated b- (red) and y- (blue) peptide fragments 
that allow for the mapping of the site of glycosylation as indicated by asterisk(*). 
Cleavage of the glycan structure from the peptide backbone via PNGase F 
digestion results in deamidation of asparagine and conversion to aspartic acid. 
Mass spectra indicate that Asn-39 is N-glycosylated. B, Western blot analysis of 
cell lysates of transfected HEK 293 cells expressing C-terminal FLAG-tagged 
wild-type (WT) CTRP12 or the single mutants (N39Q, N297Q, or N287Q). C, 
Western blot analysis of cell lysates of transfected HEK 293 cells expressing N-




Impact of Asn-39 glycosylation on CTRP12 cleavage 
We used the N39Q and N39A mutant constructs to determine the role of Asn-39 
glycosylation in modulating CTRP12 cleavage. Relative to the wild-type (WT) 
protein, we observed a significant enhancement of CTRP12 cleavage in the N39Q 
and N39A mutants when expressed in HEK 293 cells (Fig. 3A-B, D-E). The ratio 
of secreted gCTRP12 to full-length protein indicates a significant increase in 
proteolytic cleavage. Replacing Asn-39 with either glutamine or alanine did not 
affect protein secretion (Fig. 3C,F). To rule out structural changes due to N39Q or 
N39A replacements, we also mutated Thr-41 (in the context of N-X-S/T) to Ala. As 
expected, N-glycosylation was abolished in the T41A mutant (Fig. 3G). Again, loss 
of glycosylation resulted in enhanced CTRP12 cleavage (Fig. 3H), further 
confirming that Asn-39 glycosylation is indeed modulating the extent of CTRP12 
cleavage. Interestingly, Thr-41 appears to influence protein secretion; replacing 
Thr-41 with alanine resulted in greater protein secretion (Fig. 3I). It is known that 
N-linked glycosylation influences protein stability during synthesis (45). To address 
whether N39Q and T41A mutations affect protein stability, we performed a 
cycloheximide chase experiment. Cycloheximide blocks new protein synthesis; 
this allows us to examine the turnover of mutant CTRP12 and hence their stability 
relative to wild-type protein. A 6 hr chase with cycloheximide indicated that both 
the N39Q and T41A mutants were significantly less stable and had faster turnover 







Figure 3.  Asn-39 glycosylation regulates CTRP12 cleavage and stability. 
Western blot analysis of cell lysate and supernatant of transfected HEK 293 cells 
expressing wild-type (WT) CTRP12 or the N39Q (A), N39A (D), and T41A (G) 
mutants. Quantification of the ratio of cleaved to full-length (FL) protein (the 
cleavage index) in supernatant for N39Q (B), N39A (E), and T41A (H). 
Quantification of the ratio of secreted to intracellular CTRP12 (the secretion 
index) in supernatant for N39Q (C), N39A (F), and T41A (I). (J) A 6 hr 
cycloheximide chase analysis of WT and N39Q mutant. (K), Quantification of the 
relative protein stability of N39Q relative to wild-type CTRP12 protein. (L) A 6 hr 
cycloheximide chase analysis of T41A mutant. (M) Quantification of the relative 
protein stability of T41A relative to wild-type CTRP12 protein. N=6 (each lane 




Complex-type glycans influence CTRP12 cleavage  
Increased cleavage of the N39Q mutant suggests that the presence of glycans on 
Asn-39—located relatively close to the conserved cleavage site at Lys-91—may 
influence the cleavage efficiency of the Golgi-localized endopeptidase 
PCSK3/furin (46). To test this, we expressed wild-type CTRP12 protein in N-
acetylglucosaminyltransferase I-deficient (GnTI) HEK 293 cells (35).  We 
confirmed the absence of GnTI/MGAT1 mRNA and protein in the GnTI-deficient 
HEK 293 cells (Fig. 4A-B). Loss of GnTI enzyme prevents the generation of 
complex-type glycans in the Golgi (35). Proteins decorated with complex-type N-
linked glycans as they transit through the Golgi are resistant to endoglycosidase 
H (Endo H) digest.  As expected, in wild-type HEK 293 cells with intact GnTI 
activity, CTRP12 protein was susceptible to PNGase F digest and also partially 
(the pool that acquired complex glycans in the Golgi) resistant to Endo H digest 
(Fig. 4C-D). In contrast, in HEK 293S cells that lack GnTI activity, the entire 
intracellular pool of CTRP12 (with only high mannose-type glycans) was 
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susceptible to Endo H digest (Fig. 4D). Inability to generate CTRP12 containing 
complex-type N-glycans in the Golgi resulted in enhanced cleavage of the secreted 
protein (Fig. 4E-F). We also observed greater secretion of CTRP12 protein in 
GnTI-deficient HEK 293S cells (Fig. 4G), likely reflecting shorter transit time 
through the trafficking pathway in the absence of glycan remodeling in the Golgi. 
We could reverse the enhanced cleavage and secretion in GnTI-deficient cells by 







Figure 4.  Complex-type glycans influence CTRP12 cleavage. A, PCR 
amplification of human GnTI/MGAT1 mRNA in wild-type HEK 293 cells and GnTI-
deficient HEK 293S cells. The ~1.5 kb amplicon includes the entire coding region of 
GnTI. B, Western blot analysis of endogenous GnTI protein in wild-type (WT) 
HEK293 cells and GnTI-deficient HEK293S cells. C-D, Immunoblot analysis (using 
anti-FLAG antibody) of CTRP12 expressed in HEK 293 (GnTI +) and HEK 293S 
(GnTI -) cells. Cell lysates were subjected to PNGaseF (C) or Endoglycosidase H 
(D) treatment before Western blot analysis.  E, Western blot analysis of cell lysate 
and supernatant of transfected HEK 293 cells with (+) or without (-) N-
acetylglucosaminyltransferase I (GnTI) activity involved in N-glycan remodeling in 
the Golgi compartment. F, Quantification of the ratio of cleaved to full-length protein 
(the cleavage index) in the supernatant. G, Quantification of the ratio of secreted to 
intracellular CTRP12 (the secretion index). H, Western blot analysis of cell lysate 
and supernatant of GnTI-deficient HEK 293 cells re-expressing wild-type human 
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GnTI/MGAT1. I, Quantification of the ratio of cleaved to full-length protein (the 
cleavage index) in the supernatant. J, Quantification of the ratio of secreted to 
intracellular CTRP12 (the secretion index). N=6 (each lane represents a different 
sample from an independent transfection); *p<0.05; ****p<0.0001 
 
 
Modulation of CTRP12 cleavage, secretion, and protein stability by Asn-297 
Although the conserved Asn-297 is not glycosylated, we generated and tested the 
impact of Asn-297 mutation on CTRP12 cleavage. Surprisingly, either the N297Q 
or the N297A mutation resulted in enhanced cleavage of the protein (Fig. 5A-B, 
D-E). Interestingly, replacing Asn-297 with alanine, but not glutamine, reduced 
protein secretion as judged by the ratio of secreted to intracellular CTRP12 protein 
(Fig. 5F). To further ensure that Asn-297 modulates CTRP12 cleavage through a 
non-glycosylated mechanism distinct from Asn-39, we replaced Ser-299 (within 
the N297-X-S299 glycosylation motif) with alanine. The N-X-S/T is the critical 
recognition motif needed for N-glycosylation (47); mutation of Ser or Thr within this 
motif will abolish N-glycosylation. Because Asn-297 was not glycosylated, we 
predicted that the S299A mutation would not enhance CTRP12 cleavage as seen 
in the N297Q mutant. While consistent with our prediction, the S299A mutation 
unexpectedly abolished protein secretion (Fig. 5G). To address whether N297Q 
mutation affects protein stability, we performed a cycloheximide chase experiment. 
A 6 hr chase with cycloheximide indicated that N297Q mutant is less stable and 






Figure 5.  Non-glycosylated Asn-297 independently regulates CTRP12 cleavage 
and stability. Western blot analysis of cell lysate and supernatant of transfected 
HEK 293 cells expressing wild-type (WT) CTRP12 or the N297Q (A), N297A (D), 
and S299A (G) mutants. Quantification of the ratio of cleaved to full-length (FL) 
protein (the cleavage index) in supernatant for N297Q (B) and N297A (E). 
Quantification of the ratio of secreted to intracellular CTRP12 protein (the 
secretion index) for N297Q (C) and N297A (F). H, A 6 hr cycloheximide chase 
analysis of N297Q mutant. I, Quantification of the relative protein stability of 
N297Q relative to wild-type CTRP12 protein (WT data shown in Fig. 3J). N=6 
(each lane represents a different sample from an independent transfection); 





Asn-39 and Asn-297 independently modulate CTRP12 cleavage 
Since both Asn-39 and Asn-297 affect CTRP12 protein cleavage, we next 
determined whether the double mutant (N39Q/N297Q) would have an additive 
effect on cleavage. Indeed, we observed near complete and maximum CTRP12 
cleavage in the double mutant (N39Q/N297Q) (Fig. 6). Single mutation of Asn-39 
and Asn-297 increases cleavage index 10-60-fold (Fig. 3 and 6) and 2.5-fold (Fig. 
5), respectively. In the N39Q/N297Q double mutant, we observed >200-fold 
increase in the cleavage index (Fig. 6). These results suggest that Asn-39 and 
Asn-297 contribute independently to CTRP12 cleavage. Together, our results 
suggest that Asn-39 and Asn-297 modulate CTRP12 cleavage via glycosylation-







Figure 6.  Asn-39 and Asn-297 independently regulate CTRP12 cleavage. A, 
Western blot analysis of cell lysate and supernatant of transfected HEK 293 cells 
expressing wild-type (WT) CTRP12 or the N39Q/N297Q double mutant. B, 
Quantification of the ratio of cleaved to full-length (FL) protein (the cleavage 
index) in supernatant for WT and N39Q/N297Q double mutant as shown in A. C, 
Quantification of the ratio of secreted to intracellular CTRP12 protein (the 
secretion index) for WT and N39Q/N297Q double mutant as shown in A. D, A 
side-by-side comparison of WT, N39Q single mutant, and N39Q/N297Q double 
mutant. E, Quantification of the ratio of cleaved to full-length (FL) protein (the 
cleavage index) in supernatant for WT, N39Q, and N39Q/N297Q as shown in D. 




Furin-mediated cleavage of CTRP12 
We previously identified furin/PCSK3 as the proprotein convertase that cleaves 
CTRP12 at Lys-91 (24). We predicted that CTRP12 cleavage would be largely 
abolished in cells that lack furin or in which furin activity is pharmacologically 
inhibited by a furin-specific inhibitor. The peptidyl chloromethylketone (decanoyl-
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RVKR-CMK) binds to furin catalytic site and specifically inhibits it enzymatic activity 
(48-50). Cleavage of N39Q/N297Q (the double mutant with maximum cleavage) 
was also completely abolished by pharmacological inhibition of furin in HEK 293 
cells (Fig. 7A-B). Due to a single nucleotide deletion in the furin gene that results 
in truncation of the protein, the human colon carcinoma cell line LoVo lacks furin 
endopeptidase activity (41). When we expressed the wild-type CTRP12 protein in 
LoVo cells, CTRP12 cleavage was abolished (Fig. 7C). When we re-expressed 
mouse furin in LoVo cells that lack a functional furin gene, we restored CTRP12 
cleavage (Fig. 7C-D). These results indicate that the Golgi-localized furin is indeed 









Figure 7.  Furin-mediated cleavage of CTRP12. A, Western blot analysis of cell 
lysate and supernatant of transfected HEK 293 cells expressing the maximally 
cleaved CTRP12 double mutant (N39Q/N297Q) treated with vehicle control or 
furin/PCSK3 inhibitor. B, Quantification of the ratio of cleaved to full-length (FL) 
protein (the cleavage index) in supernatant as shown in A. C, Western blot 
analysis of cell lysate and supernatant of transfected LoVo cells co-expressing 
the maximally cleaved CTRP12 double mutant (N39Q/N297) and mouse furin. 
LoVo cell lacks a functional furin gene and hence the double mutant is not 
cleaved. Furin re-expression restore maximal cleavage. D, Quantification of the 
ratio of cleaved to full-length (FL) protein (the cleavage index) in supernatant as 
shown in C. N=6 (each lane represents a different sample from an independent 





Asn-287 is required for CTRP12 secretion 
In contrast to Asn-39 and Asn-297, replacing the non-glycosylated Asn-287 with 
either glutamine or alanine completely prevented CTRP12 secretion (Fig. 8A-B). 
Endoglycosidase H (Endo H) digestion can be used to assess whether an N-
glycosylated protein is located in the endoplasmic reticulum (ER; sensitive to Endo 
H digest) or Gogi (resistant to Endo H digest) (51). Endo H digest followed by 
immunoblot analysis indicated that the N287Q mutant was retained in the ER (Fig. 
8C). The mutant protein was misfolded and formed higher molecular weight protein 
aggregates (Fig. 8D). To further ensure that Asn-287 influences protein folding in 
the ER through a non-glycosylated mechanism, we replaced Ser-289 (within the 
N287-X-S289 motif needed for glycosylation) with alanine. Because Asn-287 is not 
glycosylated, we predicted that the S289A mutant would not be misfolded and 
retained in cells as seen in the N287Q or N287A mutant. Indeed, consistent with 
our hypothesis, the S289A mutant was robustly secreted from cells (Fig. 8E). 
Given that Asn-287 plays a critical role in proper protein folding, we also predicted 
that the double (N39Q/N287Q) or triple (N39Q/N287Q/N297Q) mutant would also 
be retained in the cells. Indeed, in the double and triple mutants, CTRP12 failed to 






Figure 8.  The non-glycosylated Asn-287 is required for proper protein folding 
and secretion. A-B, Western blot analysis of cell lysate and supernatant of 
transfected HEK 293 cells expressing wild-type (WT) CTRP12 or the N287Q (A) 
and N287A (B) mutant. C, Western blot analysis of Endo H digested CTRP12 
(N287Q mutant) found in transfected cell lysate. D, Formation of higher 
molecular weight protein aggregate of N287Q mutant in transfected cells. Cell 
lysates were heated at 95°C for 5 min in the presence (+) or absence (-) of 
reducing agent β-ME (β-mercaptoethanol) prior to Western blotting. E, Western 
blot analysis of cell lysate and supernatant of transfected HEK 293 cells 










Figure 9.  The CTRP12 double and triple mutants also failed to be secreted. A-
B, Western blot analysis of cell lysate and supernatant of transfected HEK 293 
cells expressing wild-type (WT) CTRP12 or the double (N39Q/N287Q) and triple 
(N39Q/N287Q/N297Q) mutants. N=6 (each lane represents a different sample 





Impact of glucosamine treatment on CTRP12 cleavage 
Glucose that fluxes through the hexosamine biosynthesis pathway (HBP) can be 
used to generate UDP-N-acetylglucosamine (UDP-GlcNAc), an essential sugar-
nucleotide substrate for protein glycosylation. In the diabetic state characterized 
by hyperglycemia, the flux through the HBP is greatly enhanced, leading to 
increased production of UDP-GlcNAc (52,53). Exogenous supplementation of cells 
with glucosamine can increase intracellular pools of UDP-GlcNAc (53,54), which 
can, in turn, disrupt N-glycosylation of proteins(55) by interfering with the synthesis 
of dolichol-linked oligosaccharides (36). We previously showed that in obese and 
diabetic mice, a greater proportion of the cleaved gCTRP12 is found in plasma. 
We therefore tested whether increasing the intracellular concentration of UDP-
GlcNAc by exogenous supplementation of glucosamine affects CTRP12 cleavage. 
Indeed, when cells were treated with 5 mM of glucosamine, total amount of N-
linked glycosylated proteins was significantly reduced (Fig. 10A-B), consistent 
with previous studies (36). At 5 mM glucosamine—a dose that affects protein N-
linked glycosylation—we observed only a modest increase in one of the three 
major ER stress pathways, as indicated by elevated ATF-6 levels but not that of 
CHOP and the spliced isoform of XBP-1 (Fig. 10C). While 5 mM glucosamine 
treatment did not affect CTRP12 protein secretion (Fig. 10F), it significantly 
enhanced CTRP12 protein cleavage (Fig. 10D-E). At a dose of 1 mM, at which 
glucosamine has no effects on N-glycosylation (36), we did not observe an 
increase in CTRP12 cleavage (not shown). These results are consistent with the 
role of N-glycosylation in modulating the extent of proteolytic processing. Because 
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N-linked glycosylation of Asn-39 also affects protein stability during synthesis (Fig. 
3), we tested if glucosamine treatment would likewise decrease CTRP12 protein 
stability. Cycloheximide chase experiment indicated that CTRP12 was less stable 








Figure 10.  Impact of hexosamine biosynthesis pathway on CTRP12 cleavage 
and stability. A-B, Quantification of glycosylated proteins (relative to total) in HEK 
293 cells treated with 5 mM of glucosamine (GlcN) for 48 hr using Pro-Q emerald 
3000 (A) or biotin-conjugated concanavalin A (B). Each lane represents an 
independent biological sample. C, Western blot quantification of three major ER 
stress pathways (XBP1, CHOP/GADD153, ATF-6) in HEK 293 cells treated with 
vehicle control or 5 mM glucosamine. XBP-1s refers to the spliced isoform of 
XBP-1. D, Western blot analysis of cell lysate and supernatant of transfected 
HEK 293 cells expressing wild-type (WT) CTRP12 treated with 5 mM 
glucosamine. E, Quantification of the ratio of cleaved to full-length (FL) protein 
(the cleavage index) in supernatant of cells treated with glucosamine. F, 
Quantification of the ratio of secreted to intracellular CTRP12 protein (the 
secretion index) as shown in D. G, A 6 hr cycloheximide chase experiment of 
HEK 293 cells treated with 5 mM glucosamine. H, Quantification of the relative 
protein stability of CTRP12 in glucosamine-treated cells versus non-treated 
controls (same as the top panel in Fig. 3J). N=6 (each lane represents a different 




We previously showed that the Golgi-localized endopeptidase furin/PCSK3 
cleaves CTRP12 at the conserved Lys-91 to generate the shorter globular 
gCTRP12 isoform (24). In the present study, we identified N-glycosylation as an 
important posttranslational modification that can modulate the extent of proteolytic 
processing by furin/PCSK3. Complete inhibition of N-linked glycosylation by 
tunicamycin significantly increased the ratio of cleaved globular isoform to full-
length CTRP12 secreted into the conditioned medium. There are three potential 
N-linked glycosylation sites (Asn-39, Asn-287, and Asn-297) that conform to the 
consensus Asn-X-Ser/Thr motif in mouse CTRP12. Asn-39 and Asn-287 are 
conserved from zebrafish to human, whereas Asn-297 is conserved in mouse, 
chicken, xenopus, and zebrafish (24). Each of these conserved Asn residues 
 
 56 
appears to play an independent role in modulating either the folding, secretion, 
stability, or proteolytic cleavage of CTRP12. 
 
For polypeptides that contain N-glycosylation sites, addition of glycan is initiated 
by the en bloc transfer of a 14-sugar moiety, Glc3Man9GlcNAc2, from the dolichol 
lipid carrier to the asparagine residues (within the N-X-S/T sequence) as the 
polypeptides are co-translationally translocated into the ER (42). The 14-sugar 
glycans get extensively trimmed by glycosidases in the ER, and the resulting 
oligomannose-type glycans get further processed and converted to hybrid and 
complex type oligosaccharides in the Golgi (42). The Golgi-resident 
glycosyltransferase GnTI (encoded by MGAT1 gene) converts Man5GlcNAc2 to 
GlcNAcMan5GlcNAc2, a critical initial step needed for all other subsequent glycan 
processing in the Golgi (56). In the absence of GnTI, only homogenous 
oligomannosidic type N-glycans (Man5GlcNAc2) are present on glycoproteins 
(35,57). Since furin/PCSK3 is a Golgi-localized endopeptidase (46,58) responsible 
for the proteolytic processing of endogenous CTRP12 in adipocytes (24), we took 
advantage of the HEK 293 cells lacking GnTI to address whether this type of N-
glycan impacts CTRP12 cleavage. In GnTI-deficient cells, we also observed 
enhanced cleavage of wild-type CTRP12. These results suggest that the presence 
of hybrid and complex-type glycans plays a role in modulating furin-mediated 
cleavage of its substrate, CTRP12, due to N-glycan processing and remodeling in 




Interestingly, we also observed enhanced cleavage of the N297Q mutant even 
though Asn-297 is not glycosylated. Asn-297 and Asn-39 are located far apart in 
the linear sequence of the CTRP12 protein. When we mutated both Asn-39 and 
Asn-297 to Gln in the double mutant (N39Q/N297Q), nearly all the full-length 
proteins were cleaved. These results suggest that Asn-39 and Asn-297 act 
independently to modulate CTRP12 cleavage. Given that Asn-297 is located close 
to the C-terminus of the protein and Asn-39 is located 54 amino acids upstream of 
the Lys-91 cleavage site, how these two sites independently modulate furin 
cleavage of CTRP12 remains unclear. The lack of structural data on CTRP12 
precludes a molecular explanation and is a limitation of the present study. 
Structural information on the C-terminal globular domain (but not full-length 
protein) exists for CTRP5 (59), CTRP10/C1ql2, CTRP13/C1ql3, CTRP14/C1ql1 
(60). The C-terminal globular domain of CTRP12, however, shares only 16-24 % 
amino acid identity to these related family members, thus precluding molecular 
modeling of CTRP12 based on these distantly related structures. Despite this 
limitation, we speculate that in the fully folded state, both Asn-39 and Asn-297 
could lie in relative close proximity to the furin cleavage site. The branches of N-
linked glycans can reach more than 3 nm from the protein surface; further, the 
bulky and mobile carbohydrate groups are also branched (61). As such, the N-
glycans could function as independent domains (61). The size and charge of the 
complex-type glycans on Asn-39 could limit furin access to the Lys-91 cleavage 
site on CTRP12. Alternatively, complex-type glycans may induce conformational 
changes in CTRP12 that would make it a poor substrate for furin, causing its 
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absence to favor a conformation that promotes furin recognition and cleavage 
within the secretory pathway. Interestingly, Lassa virus glycoprotein GP-C 
contains eleven N-glycosylation sites, six of which are required for proteolytic 
processing by the proprotein convertase PCSK8 (SK-I/S1P) (62). Opposite to that 
of CTRP12 described here, abolishing glycosylation at either position 81, 91, 101, 
121, 367, or 375 by site-directed mutagenesis in Lassa virus glycoprotein GP-C 
completely blocked its cleavage by PCSK8 at Arg-260 (62). Based on these 
results, the authors suggest that N-glycosylation may be needed for correct 
conformation of the viral glycoprotein to be proteolytically processed by PCSK8.              
 
GalNAc type O-glycosylation close to the cleavage site plays an important role in 
modulating proprotein convertase cleavage of secretory proteins (63-67). 
Specifically, O-linked glycans protect the secreted protein from inactivation by 
proprotein convertase cleavage. In all these cases, the O-glycosylated Ser or Thr 
residue lies within a few amino acids of the cleavage site (63-67). Our current 
findings represent a novel example of how disruptions in N-glycan biosynthesis in 
the ER and differential processing of N-linked glycans in the Golgi can affect the 
posttranslational cleavage of a secreted protein by proprotein convertases. Rather 
than inactivating the protein, proteolytic cleavage alters the ratio of full-length to 
cleaved isoforms of CTRP12 with potentially different biological functions (24). A 
vast majority of N-glycosylation sites are thought to be glycosylated (68) and a 
large number (~3,500) of secreted proteins are also believed to be processed by 
proprotein convertases (69). Thus, our results may have broader implications for 
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understanding crosstalk between complex N-linked glycan remodeling and other 
forms of regulation (e.g., proteolytic cleavage) in the Golgi compartment. 
Consistent with its importance in N-linked glycan remodeling, targeted disruption 
of the Mgat1 gene encoding GnTI in mice results in embryonic lethality (70,71).  
 
While Asn-39 and Asn-297 modulate the extent of CTRP12 cleavage, they are not 
required for protein secretion. Single (N39Q and N287Q) or double (N39Q/N297Q) 
mutants of CTRP12 are readily secreted from cells. In striking contrast, mutating 
Asn-287 to Gln completely abolished CTRP12 secretion. The N287Q or N287A 
mutant was retained in the ER; each still possesses high mannose-type glycans 
(on Asn-39) that can be acted upon by Endo H glycosidase. Secretory proteins 
that have exited the ER and transited to the Golgi and trans-Golgi network (TGN) 
have acquired hybrid or complex-type N-glycans that are resistant to Endo H 
action. Further, the N287Q mutant migrated as a large molecular aggregate 
compared to wild-type CTRP12 on immunoblot. These results suggest that Asn-
287 is required for proper protein folding, and its absence results in protein 
misfolding, aggregation, and retention in the ER. Consistent with its importance in 
protein folding, Asn-287 is conserved in zebrafish, frog, chicken, mouse, and 
human (24). 
 
One of the most important functions of N-glycosylation is to assist in protein folding 
in the ER (42,61). The ER chaperones calnexin and calreticulin recognize and bind 
to specific N-glycan structures (e.g., Glc1Man9-6GlcNAc2) on glycoproteins; 
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correctly folded proteins will then be released from the lectin chaperones and 
transported to the Golgi with the help of other membrane-bound lectins (e.g, 
ERGIC-53) (72). Incorrectly folded protein will be retained in the ER and be 
disposed of via several different mechanisms. Although Asn-287 can potentially 
be glycosylated, site-directed mutagenesis of Asn-287 suggests that this residue 
is not glycosylated. Further, replacing Ser-289 (within the N-X-S glycosylation 
motif) with Ala did not recapitulate the protein misfolding phenotype of the N287Q 
mutant, as would be predicted if N-linked glycosylation of Asn-287 is important for 
proper protein folding and secretion. Importantly, complete inhibition of N-
glycosylation by tunicamycin affected CTRP12 cleavage but not protein secretion. 
Together, our results point to a critical structural role for Asn-287 in proper protein 
folding, independent of glycosylation.  
 
In addition to facilitating protein folding in the ER, N-linked glycosylation can also 
influence protein stability (45). Replacing Asn-39 with glutamine or mutating Thr-
41 (in the context of N-X-T glycosylation motif) not only affects the extent of 
proteolytic cleavage of CTRP12 by the Golgi-localized furin, it also reduces protein 
stability and enhances protein turnover during synthesis. Consistent with the role 
of glycosylated Asn-39 in modulating CTRP12 protein stability, reducing N-linked 
protein glycosylation by exposing cells to exogenous glucosamine also decreases 
CTRP12 stability and increases its turnover.  It appears that the non-glycosylated 
Asn-297, when mutated to glutamine, also reduces CTRP12 protein stability during 
synthesis.  Unstable or misfolded protein is generally disposed of via the 
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endoplasmic reticulum associated degradation (ERAD) pathway (73). Thus, only 
properly folded CTRP12 protein will exit the ER and move to the Golgi where it can 
be proteolytically processed by the Golgi-localized furin. Given that ERAD occurs 
in the ER whereas furin cleavage takes place in the Golgi, this suggests that N-
linked glycosylation can influence both the protein quality control (i.e., stability) and 
posttranslational processing of CTRP12 as it traverses through the different 
membrane compartments of the cell.  
 
In the context of obesity and diabetes, high circulating blood glucose increases the 
generation of UDP-GlcNAc via the hexosamine biosynthesis pathway (52). Excess 
production of UDP-GlcNAc by exogenous supplementation of glucosamine can 
disrupt N-glycosylation in multiple different cell types in vitro and in vivo (36-38). 
Glucosamine (>5 mM) interferes with the  biosynthesis of dolichol-linked 
oligosaccharides (36), leading to the inhibition of N-glycosylation. In animal models 
of obesity and diabetes, a significantly greater proportion of CTRP12 is cleaved 
(4,24). For this reason, we sought to address whether increasing the flux through 
the hexosamine biosynthesis pathway would alter the ratio of full-length protein to 
cleaved globular isoform secreted from cells. As would be predicted from the 
deleterious role of glucosamine on protein N-glycosylation, exogenous 
supplementation of glucosamine resulted in enhanced CTRP12 cleavage, an 
effect comparable to cells treated with tunicamycin. Since the flux through the 
hexosamine biosynthesis pathway is directly correlated with glucose 
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concentrations, this pathway may account, at least in part, for the greater CTRP12 
cleavage seen in obese and diabetic animal models.  
 
In summary, each of the conserved asparagine residues (Asn-39, Asn-287, and 
Asn-297) on CTRP12 plays an important role in either regulating proteolytic 
processing by furin endopeptidase or proper protein folding, stability, and secretion 
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Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with 
metabolic function and a role in stress erythropoiesis. Despite its importance in 
physiologic processes, biochemical characterization of the protein is lacking. Here, 
we show that multiple protein modifications are critical for myonectin secretion and 
multimerization. Abolishing N-linked glycosylation by tunicamycin, glucosamine 
supplementation, or glutamine substitutions of all four potential Asn glycosylation 
sites blocked myonectin secretion. Mass spectrometry confirmed that Asn-229 and 
Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented 
myonectin secretion. Although Asn-319 is not identified as glycosylated, Gln 
substitution caused protein misfolding and retention in the endoplasmic reticulum. 
Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper 
protein folding; Ala substitution of either site inhibited protein secretion. In contrast, 
Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein 
secretion, suggesting endoplasmic reticulum retention that facilitates myonectin 
oligomer assembly. Secreted myonectin consists of trimers, hexamers, and high 
molecular weight (HMW) oligomers. Formation of higher-order structures via inter-
molecular disulfide bonds depended on Cys-142 and Cys-194, whereas the C142A 
mutant formed almost exclusively trimers and the C194 mutant was impaired in 
HMW oligomer formation. Most Pro residues within the short collagen domain of 
myonectin were also hydroxylated, a modification that stabilized the collagen triple 
helix. Inhibiting Pro hydroxylation or deleting the collagen domain markedly 
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reduced protein secretion. Together, our results reveal key determinants important 
for myonectin folding, secretion, and multimeric assembly and provide a basis for 




Beyond its necessity for locomotion, skeletal muscle regulates whole-body 
metabolism through postprandial glucose uptake (1). Skeletal muscle secretes 
many proteins, referred to as myokines, which mediate endocrine crosstalk 
between muscle and other tissue compartments to facilitate integrative control of 
energy homeostasis (2-4). Our efforts to discover novel endocrine factors that 
regulate inter-organ communications led to the identification and characterization 
of myonectin (CTRP15), a myokine produced by skeletal muscle in the basal state 
(5,6) and further induced by exercise (5,7).  
 
Myonectin belongs to the larger C1q/TNF-related protein (CTRPs) family, 
members of which share a common C-terminal globular C1q domain (5,8-14). 
Gain- and loss-of-function studies in vivo demonstrate an important role for 
myonectin in modulating local (liver and adipose tissue) and systemic lipid 
metabolism (5,15), as well as conferring a protective function in the heart in the 
context of ischemia reperfusion injury (7). Independent of its metabolic and 
cardiovascular function, myonectin/erythroferrone plays important roles in stress 
erythropoiesis (16-21). In response to severe blood loss or anemia, erythroferrone 
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expression is markedly induced in bone marrow and spleen by erythropoietin; 
elevated plasma erythroferrone then mobilizes iron stores in the liver needed for 
erythropoiesis by suppressing the expression of hepcidin. Dysregulation of the 
erythroferrone-hepcidin axis contributes to iron overload in a mouse model of β-
thalassemia (22,23) and in humans with myelodysplastic syndrome (24,25). 
Although dispensable for embryogenesis, erythroferrone may also play a role in 
development in a species-specific manner; knockdown of eryrthroferrone in 
Xenopus disrupts proper vascular network formation and primitive blood circulation 
(26).  
 
Like all C1q family members (14,27-30), myonectin forms trimers as its 
basic structural unit; individual trimers are further assembled into higher-order 
structures such as hexamers and high molecular weight (HMW) oligomers (e.g., 
12-18 mer) (5). In the case of adiponectin and CTRP12, different oligomeric forms 
have distinct biological activities and signaling properties (31-34). While the 
physiological functions of myonectin/erythroferrone are newly emerging and 
actively pursued, basic biochemical characterization of the protein is lacking, and 
the factors that influence myonectin secretion and its higher-order structural 
assembly are unknown. We aimed to uncover critical determinants—focusing on 
protein modifications—that regulate myonectin folding, secretion, and 




Our findings revealed key determinants and protein modifications important 
for myonectin folding, secretion, and multimeric assembly. This knowledge will 
inform future structure/function studies assessing naturally occurring 
polymorphisms that potentially alter protein modifications of 
myonectin/erythroferrone and their impact on secretion (and hence circulating 
level), multimerization, and biological activity.    
 
Materials and methods 
 
Materials 
Tris(2-carboxyethyl)phosphine (TCEP) was obtained from Thermo Scientific 
(Rockford, IL). Mouse monoclonal anti-FLAG M2 antibody was purchased from 
Sigma-Aldrich (St. Louis, MO). Glucosamine, Iodoacetamide, and tunicamycin 
were obtained from Sigma-Aldrich. Trypsin and chymotrypsin were purchased 
from Promega (Madison, WI), hydrazine resin was from Bio-Rad (Hercules, CA), 
and peptide N-glycosidase F (PNGase F) and endoglycosidase H (Endo H) were 
from New England Biolabs (Ipswich, MA). The selective collagen prolyl 4-
hydroxylase (CP4H) inhibitor [6-(5-Ethoxycarbonyl-thiazol-2-yl)-nicotinic acid 








All C-terminal FLAG epitope-tagged mouse myonectin/erythroferrone/CTRP15 
(NP_775571) single, double, and quadruple mutant constructs (N229Q, N281Q, 
N292Q, N319Q, S321A, N229Q/N281Q, C142A, C194A, C273A, C278A, 
C142A/C194A) were generated by either site-directed mutagenesis using a 
QuikChange kit (Stratagene, San Diego, CA) or by GenScript (Piscataway, NJ). 
The quadruple Asn mutant (N229Q/N281Q/N292Q/N319Q) is referred to as 4Q 
mutant throughout the text. The deletion mutant used in this study includes 
∆Collagen (collagen domain deleted; amino acid 97-114). Each cDNA insert was 
cloned into the expression vector pCDNA3.1 (+) (Invitrogen, Carlsbad, CA). All 
constructs were verified by DNA sequencing.  
 
Determination of signal peptidase cleavage site 
Recombinant mouse wild-type myonectin was produced in mammalian HEK 293 
cells and purified as described previously (5). Ten to twenty micrograms of purified 
protein were separated by SDS-PAGE, transferred to polyvinylidene fluoride 
(PVDF) membrane, and subjected to N-terminal amino acid sequencing at the 
synthesis and sequencing facility at Johns Hopkins University.  
 
Protein digestion and N-linked glycopeptide enrichment 
Urea was added to 25 μg of purified recombinant mouse myonectin (in 25 mM 
HEPES, 135 mM NaCl, pH 8) to a final concentration of 8 M to aid in protein 
digestion by proteases. Myonectin protein was reduced with 10 mM TECP, and 
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then alkylated with 15 mM iodoacetamide. 50 mM triethylammonium bicarbonate 
was added to reduce urea concentration to 1 M. Myonectin sample was subjected 
to trypsin (1:25 enzyme-protein ratio), followed by chymotrypsin (1:25 enzyme-
protein ratio) digest at 37°C overnight. A solid-phase extraction method of N-linked 
glycoprotein (SPEG) was used to enrich glycosylated peptide as previously 
described (35,36). Peptides were first subjected to C18 stage tip clean-up (37), 
then oxidized with 10 mM sodium periodate at room temperature for 1 h. Peptides 
were desalted using C18 stage tip before conjugation to hydrazide resin. The 
overnight coupling reaction was carried out in 80% acetonitrile, 0.1% trifluoroacetic 
acid, and 1% aniline. Non-glycosylated peptides were removed by washing the 
resin three times with 1 mL of 50% acetonitrile, 1.5 M NaCl, HPLC-H2O, and 25 
mM triethylammonium bicarbonate. Overnight incubation with 3 μL of PNGase F 
in 25 mM triethylammonium bicarbonate was carried out to release the N-linked 
glycosite-containing peptides from the resin . Released glycosite-containing 
peptides were collected after centrifugation at 3,000 x g. The resin was then rinsed 
with 50% acetonitrile twice and the washes were pooled. The peptide solution was 
desalted, dried, and reconstituted in 0.1% formic acid and subjected to mass 
spectrometry (MS) analysis. 
 
LC-MS/MS analysis and protein identification 
ESI-LC-MS/MS was used to analyze the peptides as described (38). 
Approximately ~1 μg of the N-linked glycosite-containing peptides were separated 
using a Dionex Ultimate 3000 RSLC nano system (Thermo Scientific, Waltham, 
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MA) with a 75-μm x 15-cm Acclaim PepMap100 separating column (Thermo 
Scientific) protected by a 2-cm guard column (Thermo Scientific). The mobile 
phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid/95% 
acetonitrile (B). Flow rate was set at 300 nL/min. The following gradient profile was 
used: 4-35% B for 70 min, 35-95% B for 5 min, 95% B for 10 min, and equilibrated 
in 4% B for 15 min. An Orbitrap Velos Pro mass spectrometer (Thermo Scientific) 
was used in MS analyses. Spray voltage was set at 2.2 kV. Orbitrap spectra (AGC 
1x106) were collected from 400-1800 m/z at a resolution of 60 K followed by data-
dependent HCD MS/MS (at a resolution of 7500, collision energy 35%, activation 
time 0.1 ms) of the ten most abundant ions using an isolation width of 2.0 Da. 
Unassigned and singly charged ions were rejected by Charge state screening. A 
dynamic exclusion time of 35 sec was used to discriminate against previously 
selected ions. Peptides were identified using Proteome Discoverer software 
(Thermo Scientific, ver 1.3). Spectra were searched against the 
CTRP15/myonectin/erythroferrone protein sequence [UniProtKB – Q6PGN1, 
ERFE_MOUSE]. The precursor mass tolerance was set at 20 ppm and the MS/MS 
tolerance at 0.06 Da. Parameters of the search included: variable modifications 
such as methionine oxidation (+15.99492), asparagine deamidation (+0.984016), 
and proline hydroxylation (+15.99492); fixed modification such as cysteine 
carbamidomethylation (+57.02510); digestion enzymes such as trypsin and 





Cell culture and transfection 
HEK 293A cells (ATCC) were cultured in DMEM (Invitrogen) containing 10% fetal 
bovine serum (FBS), 4 mM L-glutamine, 100 units/mL penicillin, and 100 µg/mL 
streptomycin. Transfections were carried out using Lipofectamine (Invitrogen) 
according to the manufacturer’s instructions. Twenty-four h post transfection, 
medium was replaced with serum-free Opti-MEM (Invitrogen). Both cell lysates 
and media from transfected cells were collected 24 h later. Cell lysates were 
prepared by solubilizing cells in whole cell extract buffer (20 mM Tris-HCL pH 7.5, 
150 mM NaCl, 1 mM Na2EDTA, 0.5% NP-40, and 10% glycerol) containing 
SIGMAFASTTM protease inhibitor cocktail (Sigma) and phosSTOP phosphatase 
inhibitor cocktail (Roche, Basel Swizerland). For the treatment groups, tunicamycin 
(0.5 μg/mL) or glucosamine (5 mM) was added to the culture medium 2 h before 
transfection. The dose of glucosamine used (5 mM) was known to disrupt N-
glycosylation (39-41). For experiments involving the selective CP4H inhibitor, cells 
were cultured in media containing 50 μM of diethyl-pythiDC or vehicle control 
(DMSO; equal volume) for 1 h before transfection and the inhibitor was added to 
fresh media the following day. 24 h after transfection, medium was replaced with 
serum-free Opti-MEM (Invitrogen) containing tunicamycin, glucosamine, diethyl-








For immunoblot analyses, cell lysates were suspended in loading buffer containing 
50 mM Tris, 2% SDS, 1% β-ME, 6% glycerol, and 0.01% bromophenol blue. The 
protein samples were denatured at 94°C for 15 min. Proteins were separated in 
10% or 8-16% pre-cast mini-PROTEAN TGX gel (Bio-Rad), and transferred onto 
nitrocellulose or PVDF membrane (Bio-Rad). Membranes were blocked with 5% 
non-fat milk for 1 h, followed by incubation with mouse anti-FLAG M2 (1:1000) 
overnight. Immunoblots were washed three times (5 min each) in PBS containing 
0.1% Tween-20, followed by incubation with horseradish peroxidase-conjugated 
secondary antibody (Amersham Biosciences, Little Chalfont, United Kingdom) at 
1:2,000 for 1 h. Blots were washed 3 times (5 min each) in PBS containing 0.1% 
Tween 20, developed in ECL reagent (Millipore, Burlington, MA) for 5-10 min and 
visualized with MultiImage III FluorChem ® Q (Alpha Innotech, San Leandro, CA). 
Quantification of signal intensity was performed using Image J software (42).  
 
Blue native gel electrophoresis  
Blue native PAGE was carried out based on the Invitrogen NativePAGE Novex 
Bis-Tris gel system protocol. Briefly, samples were prepared by addition of 6.25 μL 
of NativePAGE sample buffer (Invitrogen; BN2003) to 18.75 uL of conditioned 
medium of transfected HEK 293 cells. Proteins were separated on a 3-12% 1.0 
mm thick precast Bis-Tris gel (Invitrogen; BN1001) using the XCell II blot module. 
After 25 μL of prepared samples were loaded into wells, light blue cathode running 
buffer containing 0.002% Coomassie G-250 (Invitrogen; BN2004) and 1x anode 
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running buffer (Invitrogen; BN2001) were poured into the inner and outer 
chambers, respectively. The gel was run at a constant 150 volts, 15 amps, and 
4C for 150 min. 
 
Before immunoblotting, PVDF membrane (BioRad; 1620177) was incubated in 
100% methanol for 30 sec, then rinsed 2 min in distilled water and incubated in 1x 
NuPAGE transfer buffer (Invitrogen; NP00061) for 10 min. Following the run, gel 
was first incubated in transfer buffer for 2 min, then immediately transferred for 90 
min at 100 volts and 4C onto the prepared PVDF membrane using the BioRad 
Mini Trans-Blot® electrophoretic transfer cell. A stir bar was added to the cell and 
set to 350 rpm for the duration of the transfer to help maintain even buffer 
temperature and ion distribution. 
 
Following transfer, the membrane was incubated in 8% acetic acid for 15 min, 
briefly rinsed with distilled water, then incubated in 100% methanol for 2 min. After 
a brief distilled water wash, the membrane was blocked with 5% nonfat milk for 1 
h and probed with mouse anti-FLAG M2 antibody (Cell Signaling, Danvers, MA; 
8146S) at 1:500 overnight. Immunoblots were washed three times (5 min each) in 
PBS containing 0.1% Tween 20 and incubated with horseradish peroxidase-
conjugated secondary antibody (Cell Signaling; 7076S; 1:1000) for 1 h. Blots were 
washed three times (5 min each) in PBS containing 0.1% Tween 20, developed in 
ECL reagent (MilliporeSigma, Burlington, MA; GERPN2235) for 8 min, and 




Two-tailed Student’s t-tests were used in all comparison. Values were considered 





N-linked glycosylation is required for myonectin secretion 
As a secreted protein, myonectin/erythroferrone contains a hydrophobic signal 
peptide at the N-terminus. Although the SignalIP program(43) predicted that the 
signal peptide would be cleaved between Gly-26 and Val-27, N-terminal 
sequencing of purified mouse myonectin revealed “ESAE” to be the first four amino 
acids of the mature secreted protein, suggesting that the cleavage site is between 
Pro-28 and Glu-29 (Fig. 1). Although uncommon, proline at the P-1 position of the 
cleavage site was documented for other mammalian secretory and plasma 







Figure 1. Conservation of protein modification sites between mouse and human 
myonectin. A, Domain structure of mouse myonectin. The four potential N-linked 
glycosylation sites (Asn-229, Asn-281, Asn-292, and Asn-319) that conform to the 
N-X-S/T motif are labeled. The positions of the four cysteine residues (Cys-142, 
Cys-194, Cys-273, and Cys-278) are also labeled. The presence of a FLAG 
epitope tag (DYKDDDK) located in the C-terminus of the protein is also indicated. 
B, Multiple sequence alignment of mouse (NP_775571) and human 
(NP_001278761) myonectin. Alignment was peformed using ClustalW program 
(50). The signal peptide, signal peptidase cleavage site, N-terminal domain 1 
(NTD1), collagen domain, NTD2, and C1q/TNF-like domain are highlighted, as are 







Mouse myonectin/erythroferrone contains four potential N-linked glycosylation 
sites (Asn-229, Asn-281, Asn-292, and Asn-319) that conform to the consensus 
sequon, N-X-S/T (where X is any amino acid except proline; Fig. 1A). Three of 
these sites (Asn-229, Asn-281, Asn-319) are conserved in human myonectin (Fig. 
1B). When subjected to peptide:N-glycosidase F (PNGase F) digest, the apparent 
molecular weight of myonectin shifted on immunoblot, indicating that myonectin 
contains N-linked glycans (Fig. 2A), as we had previously shown (5). To determine 
whether N-linked glycosylation is required for proper myonectin folding and 
secretion, we used tunicamycin to completely block N-glycosylation (51,52). In 
heterologous HEK 293A cells expressing mouse myonectin, blocking N-linked 
glycosylation abolished protein secretion (Fig. 2B). UDP-N-acetylglucosamine 
(UDP-GlcNAc)—derived from the hexosamine biosynthesis pathway—is an 
essential sugar-nucleotide substrate for protein glycosylation. Excess production 
of UDP-GlcNAc by glucosamine supplementation can also disrupt N-glycosylation 
of proteins by interfering with the biosynthesis of dolichol-linked oligosaccharides 
(39). When we used 5 mM of glucosamine, a dose that reduces N-linked 
glycosylated proteins (39,53), we observed a block in myonectin secretion (Fig. 
2C). In accordance with the results obtained with pharmacologic inhibition of N-
linked glycosylation, the 4Q mutant that lacks all four potential N-linked 
glycosylation sites was also not secreted (Fig. 2D). These results indicate that 








Figure 2. N-linked glycosylation is required for myonectin secretion. A, Peptide 
N:Glycosidase F (PNGase F) digest indicating that myonectin protein contains N-
linked glycans. B, Inhibiting N-linked glycosylation by tunicamycin abolished 
myonectin secretion. C, Glucosamine (5 mM) supplementation, known to inhibit 
N-linked glycosylation, also blocked myonectin secretion. D, Substitution of all 
four potential Asn glycosylation residues (Asn-229, Asn-281, Asn-292, and Asn-
319) with Gln (the 4Q mutant) abolished protein secretion. Representative 
immunoblots probed with an anti-FLAG antibody (recognizing the FLAG epitope-
tagged myonectin) are shown. All the transfection and immunoblot experiments 







Myonectin secretion is dependent on glycosylation at Asn-229 or Asn-281 
To determine which of the four potential N-linked glycosylation sites contains 
glycans, we subjected purified recombinant mouse myonectin made in mammalian 
HEK 293 cells to mass spectrometry analysis. As indicated by mass spectra, Asn-
229 and Asn-281 were glycosylated (Fig. 3A-B). Replacing Asn-229 with Gln 
resulted in a shift of molecular weight of myonectin on immunoblot, confirming that 
Asn-229 is indeed glycosylated (Fig. 3C).  When subjected to PNGase F digest, 
the apparent molecular weight of N229Q mutant further shifted on immunoblot, 
suggesting the presence of additional N-linked glycans (Fig. 3D). Substituting Asn-
281 with Gln also resulted in a shift of molecular weight of myonectin on 
immunoblot, confirming that Asn-281 is also glycosylated (Fig. 3E). Since both 
Asn-229 and Asn-281 are glycosylated, the apparent molecular weight of N281Q 
could be further reduced by PNGase F treatment (Fig. 3F). Replacing both Asn-
229 and Asn-281 with Gln in the double mutant completely abolished protein 
secretion (Fig. 3G). Treatment with PNGase F did not result in any futher shift in 
the apparent molecular weight of the double mutant (Fig. 3H), suggesting that 
these two sites are the only ones with detected glycosylation. The double mutant 
(N229Q/N281Q) protein that was retained inside the cell was presumably 
misfolded and formed higher molecular weight protein aggregates (Fig. 3I). These 
results indicate that glycosylation of either Asn-229 or Asn-281 is necessary for 








Figure 3. Mass spectrometry and mutational analysis of N-glycosylation in 
myonectin. A-B, MS/MS spectrum of the two glycopeptides derived from purified 
myonectin (made in mammalian HEK 293 cells) identified using Proteome 
Discoverer. Higher-energy collisional dissociation (HCD) generated b- (red) and 
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y- (blue) peptide fragments that allowed for mapping the glycosylation site as 
indicated by asterisk (*). Mass spectra indicating that Asn-229 and Asn-281 are 
glycosylated. C, Immunoblot analysis of cell lysate and supernatant of 
transfected HEK 293 cells expressing wild-type (WT) myonectin or the single 
N229Q mutant. D, Peptide N:Glycosidase F (PNGase F) digest of N229Q mutant 
indicating the presence of additional N-linked glycans. E, Immunoblot analysis of 
wild-type (WT) myonectin or the N281Q mutant. F, PNGase F digest of N281Q 
mutant indicating the presence of additional N-linked glycans. G, Substitution of 
both Asn-229 and Asn-281 with Gln in the double mutant abolished myonectin 
protein secretion. H, PNGase F digest of the double mutant (N229Q/N281Q) 
indicating that these two sites are the only ones detected as glycosylated. I, 
Formation of higher molecular weight protein aggregate of the N229Q/N281Q 
double mutant in transfected cells. Cell lysates were treated with (+) or without (-) 
heat (95°C) and reducing agent β-ME (β-mercaptoethanol) prior to Western 
blotting. Representative immunoblots probed with an anti-FLAG antibody 
(recognizing the FLAG epitope-tagged myonectin) are shown. All transfection 
and immunoblot experiments were repeated at least three independent times.   
 
 
Asn-319 is required for proper protein folding 
The C-terminal peptide fragments containing Asn-292 or Asn-319 were not 
detected by mass spectrometry. Therefore, we used site-directed mutagenesis to 
assess whether these sites contain N-linked glycans. Substitution of Asn-292 with 
Gln had no impact on protein secretion, nor did it alter the apparent molecular 
weight of the protein on immunoblot (Fig. 4A), indicating that Asn-292 is not 
detected as glycosylated. In contrast, replacing Asn-319 with Gln blocked protein 
secretion, but it did not shift the apparent molecular weight of the protein on 
immunoblot (Fig. 4B), suggesting that Asn-319 is not detected as a glycosylation 
site but is required for proper protein folding. To assess whether the misfolded 
N319Q mutant is retained in the endoplasmic reticulum (ER) because it failed ER 
quality control, we subjected the cell lysate to endoglycosidase H (Endo H) 
digestion. Sensitivity to Endo H digestion (due to the presence of high mannose-
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type glycans) indicates that N319Q resides in the ER and has not transited to the 
Golgi (54). Endo H digest followed by immunoblot analysis confirmed that the 
misfolded N319Q mutant was retained in the ER (Fig. 4C). To ensure that Asn-
319 affects myonectin folding in the ER via a non-glycosylated mechanism, we 
substituted Ser-321 (within the N319-X-S321 glycosylation sequon) with Ala. N-X-
S/T is the critical recognition sequon for N-glycosylation, and substituting Ser or 
Thr within this sequon will abolish N-linked glycosylation (55). Because Asn-319 
was not glycosylated, substitution of Ser-321 with Ala should not affect protein 
folding and secretion. Indeed, the S321A mutant was robustly expressed and 
secreted from cells (Fig. 4D). These results indicate that neither Asn-292 nor Asn-
319 is glycosylated, but that Asn-319 (conserved in mouse and human) is critical 








Figure 4. Asn-292 and Asn-319 are not detected as glycosylated sites but their 
substitution impacts protein folding and secretion. A, Immunoblot analysis of cell 
lysate and supernatant of transfected HEK 293 cells expressing wild-type (WT) 
myonectin or the N292Q mutant. B, Substitution of Asn-319 with Gln blocks 
myonectin secretion. C, Sensitivity of N319Q mutant to endoglycosidase H (Endo 
H) digestion indicates that the mutant protein remains in the endoplasmic 
reticulum, presumably due to protein misfolding. D, Immunoblot analysis of WT 
myonectin or the S321A mutant. Representative immunoblots probed with an anti-
FLAG antibody (recognizing the FLAG epitope-tagged myonectin) are shown. All 








Conserved cysteine residues are important for protein folding and secretion 
Myonectin possesses four cysteine residues (Cys-142, Cys-194, Cys-273, Cys-
278) conserved between mouse and human (Fig. 1). Replacing either Cys-273 or 
Cys-278 located in the C-terminal globular domain prevented protein secretion 
(Fig. 5A). These mutants were sensitive to Endo H digest (Fig. 5B), indicating that 
they were retained in the ER, presumably due to protein mis-folding. In striking 
contrast, substituting Cys-142, located in the N-terminal domain, with Ala 
significantly enhanced myonectin secretion (Fig. 5C). Replacing Cys-194 with Ala 
also significantly increased protein secretion (Fig. 5D). When both Cys-142 and 
Cys-194 were substituted with Ala in the double mutant, we did not observe further 
enhancement of protein secretion (Fig. 5E). These results indicate the important 











Figure 5. Impact of conserved cysteine residues on myonectin secretion. A, 
Immunoblot analysis of cell lysates and supernatant of transfected HEK 293 cells 
expressing wild-type (WT) myonectin or the C273A or C278A mutant. B, 
Sensitivity of C273A and C278A mutants to endoglycosidase H (Endo H) digest 
indicates that the mutant proteins remain in the endoplasmic reticulum, 
presumably due to protein misfolding. C, Substitution of Cys-142 with Ala 
enhances myonectin secretion. The extent of protein secretion is quantified as 
the amount of secreted myonectin found in the supernatant relative to 
intracellular myonectin based on four independent experiments. D, Substitution 
of Cys-194 with Ala enhances myonectin secretion. Quantification of the relative 
protein secretion normalized to intracellular myonectin is based on four 
independent experiments. E, Substitution of both Cys-142 and Cys-194 with Ala 
in the double mutant enhances myonectin secretion. Quantification of the relative 
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protein secretion normalized to intracellular myonectin is based on three 




Cys-142 and Cys-194 are required for the assembly of hexamer and HMW 
oligomer 
All secreted proteins containing the globular C1q domain form trimers as their 
basic structural unit (14,27-30); adjacent trimers can be further assembled into 
hexamers and HMW oligomers (with 12-18 units) (9,56-58). Assembly of higher-
order structures greater than a trimer involves inter-molecular disulfide bonds 
mediated by one or more of the conserved Cys residues located in the N-terminus 
(9,32,34). We used blue native gel electrophoresis to assess if Cys-142 or Cys-
194 is required for assembly of high-order structures. Native immunoblot indicated 
that wild-type (WT) myonectin forms trimers, hexamers, and HMW oligomers (Fig. 
6A), with the approximate distribution of 52% trimer, 8% hexamer, and 40% HMW 
oligomer (Fig. 6B). Substituting Cys-142 with Ala resulted in the near-exclusive 
formation of trimers (Fig. 6A-B; 93% trimer, 0.2% hexamer, 4% HMW oligomer). 
In contrast, replacing Cys-194 with Ala had no impact on the assembly of trimers 
and hexamers, but resulted in a significant reduction (~34%) in the formation of 
HMW oligomers (Fig. 6A-B). These results indicate that both Cys-142 and Cys-
194 mediate inter-molecular disulfide bonds required for the formation of higher-





Figure 6. Formation of hexamer and higher-order oligomeric complexes depends 
on Cys-142. A, Representative blue native gel immunoblot of wild-type (WT) 
myonectin and C142A and C194A mutants. B, Quantification of the proportion 
(as % of total secreted myonectin) of trimers, hexamers, and high molecular 




Protein modification of collagen domain  
Both human and mouse myonectin/erythroferrone possess a short collagen-like 
domain located between the N-terminal domain 1 (NTD1) and NTD2 (Fig. 7A). 
This short collagen domain consists of six Gly-X-Y repeats (where X and Y are 
frequently proline or lysine), the same repeating unit found in all collagen (59). 
Proline hydroxylation and lysine glycosylation are important for the stability of the 
triple helical structure of the collagen domain (59-61). Mouse 
myonectin/erythroferrone contains nine proline residues that can be hydroxylated 
(Pro-99, Pro-101, Pro-102, Pro-104, Pro-105, Pro-107, Pro-110, Pro-111, and Pro-
113) (Fig. 7A); all nine of the proline residues are conserved in human myonectin 
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(NP_001278761). Using mass spectrometry, we provided direct evidence that the 
first six proline residues (Pro-99, Pro-101, Pro-102, Pro-104, Pro-105, and Pro-
107) are hydroxylated (Fig. 7B). The number of peptide-spectrum matches (PSM) 
for each of the six hydroxyl-proline was 42, 115, 77, 63, 54, and 7, respectively. In 
contrast, there were only 5, 1, 1, and 1 PSM that corresponded to hydroxylated 
Pro-110, Pro-111, Pro-113, and Pro-116, respectively. Although suggestive, the 
low PSM counts preclude definitive evidence for proline hydroxylation at these 
sites. These results indicate that most of the conserved proline residues within the 











Figure 7. Proline hydroxylation within the collagen domain of myonectin. A, 
Schematic showing the proline residues found in the six Gly-X-Y repeats of the 
collagen-like domain of mouse myonectin. All nine proline residues are conserved 
in human myonectin. Hydroxylated prolines as determined by mass spectrometry 
analysis are highlighted in red. B, MS/MS spectrum of the three peptides derived 
from myonectin identified using Proteome Discoverer. Higher-energy collisional 
dissociation generated b- (red) and y- (blue) peptide fragments that allow for the 
mapping of proline hydroxylation sites are indicated by asterisk(*). Mass spectra 




Inhibiting proline hydroxylation or deleting the collagen domain 
substantially impairs myonectin secretion  
We next addressed whether hydroxylation of the proline residues within the 
collagen domain of myonectin affects its expression and secretion. Collagen prolyl 
4-hydroxylase (CP4H) catalyzes the hydroxylation of proline within the collagen 
domain (62) and diethyl-pythiDC is a selective inhibitor of CP4H (63). Inhibiting 
CP4H with diethyl-pythiDC (50 μM) significantly reduced myonectin secretion from 
transfected cells (Fig. 8A-B). The G-X-Y repeats in the collagen domain promote 
the formation of triple helical structure (64,65). To determine the consequence of 
removing the short collagen domain (containing at least nine hydroxyprolines; Fig. 
7A), we generated a mutant protein lacking the collagen domain (six Gly-X-Y 
repeats). Relative to wild-type myonectin, the secretion of mutant protein lacking 
the collagen domain was also significantly (~85%) reduced (Fig. 8C-D). These 
results suggest contribution of the collagen domain and its hydroxyprolines to the 
assembly and/or stability of the basic trimeric structural unit of myonectin during 





Figure 8.  Inhibiting proline hydroxylation or deleting the collagen domain 
markedly reduces myonectin secretion. A, Immunoblot analysis of cell lysate and 
supernatant of transfected HEK 293 cells expressing wild-type (WT) myonectin 
treated with vehicle control (DMSO) or 50 μM diethyl-pythiDC (selective inhibitor 
of CP4H). B, Quantification of relative protein secretion from three independent 
experiment as shown in A. C, Immunoblot analysis of cell lysate and supernatant 
of transfected HEK 293 cells expressing wild-type (WT) myonectin or the 
collagen-deleted mutant (∆Collagen). D, Quantification of relative protein 
secretion of WT and ∆Collagen mutant based on three independent experiments. 










The findings presented here describe protein modifications critical for myonectin 
folding, secretion, and high-order structure formation. N-linked glycosylation was 
required for myonectin secretion and Cys-mediated intermolecular disulfide bond 
formation was necessary for the assembly of hexameric and HMW oligomeric 
forms of the protein. The short collagen domain, with its hydroxylated prolines, was 
needed for efficient myonectin secretion. 
 
Many secretory proteins are glycosylated as they transit through the secretory 
pathways during biosynthesis. One critical function of N-linked glycosylation is to 
assist in protein folding in the ER (66,67). This function is part of an important 
protein quality control system where dedicated ER-localized lectin chaperones 
(e.g., calnexin and calreticulin) bind to specific N-linked glycan structures on 
glycoproteins (68). Multiple rounds of capture and release by the lectin chaperones 
occur until the glycoprotein is correctly folded into its native conformation, then it 
is released from the ER and transported to the Golgi (68,69). Proteins that are 
misfolded will be retained in the ER and be degraded via the ERAD or other 
pathways (70). Likewise, N-linked glycosylation of myonectin is also critical for its 
proper folding and eventual secretion from cells. We found that either Asn-229 or 
Asn-281, when glycosylated, was sufficient for protein secretion; however, when 
glycosylation was completely abolished in the N229Q/N281Q double mutant, the 
protein failed to be secreted, presumably due to protein misfolding. These results 
were corroborated by pharmacologic inhibition of N-linked glycosylation with 
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tunicamycin or high dose of glucosamine. In accordance with their importance in 
protein folding and secretion, both Asn-229 and Asn-281 are conserved in mouse 
and human myonectin.  
 
Myonectin exists in different multimeric forms (5). Here, we showed that mature 
secreted myonectin forms trimers, hexamers, and HMW oligomers. All 
biochemically characterized C1q family members form trimers as their basic 
structural unit, a feature confirmed by crystal structures(28-30,71,72). Trimer 
formation is driven by the C-terminal globular C1q domain with its highly conserved 
hydrophobic residues located at the interface of each monomer. Higher-order 
structures greater than a trimer, however, are formed by linking multiple trimeric 
units via inter-molecular disulfide bonds (9,32,34). For this reason, we 
systematically mutated each of the four conserved Cys residues in myonectin to 
determine which is critical for the assembly of higher-order structures. Two of the 
Cys residues (Cys-273 and Cys-278) were critical for proper protein folding and 
secretion; substitution of either Cys with Ala resulted in protein misfolding and 
retention in the ER. The C1q domain located in the C-terminus of the protein forms 
a compact globular structure (28-30,71,72) and, given the location of Cys-273 and 
Cys-278 within the globular C1q domain, it is not surprising that substitution of 
either conserved Cys residue led to protein misfolding and retention in the ER. 
Because the globular domain of myonectin shares less than 30% amino acid 
identity with other related C1q family members, the existing crystal structures could 
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not be used to accurately model how mutation of Cys-273 or Cys-278 interferes 
with myonectin globular domain folding. 
  
In contrast, Cys-142 and Cys-194 play important roles in myonectin 
oligomerization. Substituting Cys-142 with Ala led to the near exclusive formation 
of trimers, indicating the critical importance of the N-terminal Cys in mediating 
inter-molecular disulfide bonds necessary for the assembly of trimers into 
hexamers and HMW oligomers. However, substituting Cys-194 with Ala 
significantly impaired, but did not abolish, the formation of HMW oligomers. This 
result suggests that Cys-194 (located near the junction between NTD2 and the 
globular C1q domain) facilitates HMW oligomer formation, but is not required. 
Thus, of the two Cys residues, only the N-terminal Cys-142 in myonectin is 
essential for the formation of higher-order hexamers and HMW oligomers. The 
conserved N-terminal Cys residue also appears to be a general feature shared by 
other C1q family members studied to date (9,32,34).   
   
Not only do Cys-142 and Cys-194 facilitate multimeric assembly of myonectin 
complexes via inter-molecular disulfide bond formation, their substitutions with 
Ala also strikingly enhanced protein secretion. The role of N-terminal Cys 
residues in regulating the rate of protein secretion was demonstrated for 
adiponectin and CTRP11, two related members of the C1q family (13,73). Our 
data suggest that myonectin may be transiently retained in the ER during its 
biosynthesis via a thiol-mediated retention mechanism, whereby Cys-142 or Cys-
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194 forms reversible disulfide bonds with ER resident oxidoreductases to 
facilitate the assembly of higher-order multimeric complexes (hexamers and 
HMW oligomers) before protein secretion. Replacing either Cys residue with Ala 
may shorten the transit time in the ER and lead to higher secretion of the basic 
trimeric complexes of myonectin. The thiol-mediated ER retention mechanism 
was first discovered in the course of understanding polymeric immunoglobulin 
(IgM) assembly and secretion in plasma cells (74,75). Cys-575 of the μ chain is 
responsible for ER retention (75) by forming disulfide bonds with resident ER 
oxidoreductases (76) and the secretory rate of additional proteins (IgA and Ig λ 
light chain) from different cells was also found to be similarly regulated (77,78). 
Of particular relevance to the present study is the assembly and secretion of 
adiponectin (a C1q family member) hexameric and HMW oligomeric complexes. 
A substantial pool of properly folded adiponectin is retained in the ER through the 
thiol-mediated ER retention mechanism involving its N-terminal Cys-39 forming a 
transient disulfide bond with the ER oxidoreductase, ERp44 (73). Abrogating this 
interaction led to enhanced secretion of adiponectin trimers. Another ER 
chaperone, Ero1-Lα, facilitates the release of adiponectin from ERp44 (73). The 
levels of these two chaperones, under different cellular and metabolic states, 
dictates the proportion of adiponectin trimers, hexamers, and HMW oligomers 
secreted from adipocytes (73). Additionally, oxidoreductase-like protein (DsbA-L) 
may also play a role in the multimerization of adiponectin (79). Based on our 
current data and previous studies, we speculate that myonectin likely employs a 
similar thiol-mediated retention mechanism to regulate the assembly and 
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secretion of different multimeric complexes, possibly in response to changes in 
cellular states. The significance and relevance of different oligomeric complexes 
of adiponectin relates to their biological activity and signaling specificity (32-34), 
differential association with disease states (80,81), and location (82). Given that 
myonectin is produced by skeletal muscle under basal conditions (5) and can be 
induced in different tissues and cell types in response to physiologic 
perturbations (7,16,17,20-22,83), future studies are warranted to determine 
whether different oligomeric complexes of myonectin/erythroferrone are 
differentially secreted by distinct cell types under different conditions. Future 
studies are also needed to assess whether there are differences in biological 
activity among different complexes of myonectin, and whether distinct complexes 
are associated with disease states (84). 
 
In addition to glycosylation and Cys-mediated multimerization, proline residues 
within the short collagen domain were hydroxylated. The protein modification of 
proline was initially found in collagens (85)  and subsequently also identified in 
other proteins containing the collagen domain (8,86,87). Proline hydroxylation by 
CP4H stabilizes the collagen triple helix (85,88,89), and does so by forming 
hydrogen bonds with water molecules surrounding the triple helix (64,90).  
Inhibiting proline hydroxylation markedly reduced myonectin secretion in our 
study. It appears that proline hydroxylation is required for efficient secretion of 
proteins containing a collagen domain, and this was observed in complement 
C1q where inhibition of proline hydroxylation also greatly reduced protein 
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secretion from cells (91).  Our data showed that myonectin lacking the short (six 
Gly-X-Y repeats) collagen domain is substantially impaired in its secretion. 
Because the basic structural unit of myonectin is a trimer, we speculate that the 
collagen triple helix and its hydroxyprolines likely confer stability to the N-terminal 
extended stalk-like structure preceding the C-terminal globular trimers. An 
example is the globular C1q domain of collagen X initiating trimerization and 
trimeric complex stabilization by the collagen triple helix (92,93).   
 
In summary, this study provided biochemical insights into key determinants and 
protein modifications important for myonectin folding, secretion, and multimeric 
assembly. One caveat of the study, however, is that myonectin secretion and 
assembly was evaluated in human embryonic kidney (HEK) cells and it is possible 
that the patterns of protein modification could be distinct in skeletal muscle and 
that further studies will be needed to investigate this possibility. Nonetheless, the 
knowledge obtained here will catalyze future structure/function studies assessing 
naturally occurring polymorphisms that alter protein modifications of 
myonectin/erythroferrone and their impact on secretion (and hence circulating 
level), multimerization, and biological activity. These changes may influence 
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Inter-organ communication mediated by secreted proteins plays a pivotal role in 
metabolic homeostasis, yet the function of many circulating secretory proteins 
remains unknown. Here, we describe the function of Protease Associated Domain 
Containing 1 (PRADC1), an enigmatic secretory protein widely expressed in 
humans and mice. In metabolically active tissues (liver, muscle, fat, heart, and 
kidney), we showed that Pradc1 expression is significantly suppressed by fasting-
and-refeeding and reduced in kidney and brown fat in the context of obesity. 
PRADC1 is dispensable for whole-body metabolism when mice are fed a low-fat 
diet. However, in obesity induced by high-fat feeding, PRADC1-deficient female 
mice have reduced weight gain and adiposity despite similar caloric intake. 
Decreased fat mass is attributed, in part, to increased metabolic rate, physical 
activity, and energy expenditure in these animals. Reduced adiposity in PRADC1-
deficient mice, however, does not improve systemic glucose and lipid metabolism, 
insulin sensitivity, liver steatosis, or adipose inflammation. Thus, in PRADC1-
deficient animals, decreased fat mass and enhanced physical activity are 
insufficient to confer a healthy metabolic phenotype in the context of an 
obesogenic diet. Our results shed light on the physiological function of PRADC1 








Regulation of systemic metabolism and energy balance requires integrative 
mechanisms involving multiple tissues and organs. Secreted hormones mediate 
inter-organ communication necessary to maintain energy homeostasis. Although 
>3,000 human genes encode proteins with a signal peptide for secretion (1-3) and 
mass spectrometry can detect over three thousand proteins in plasma (3), the 
function of most of the secretory proteins in circulation remains poorly defined or 
unknown.  
To uncover novel secreted metabolic regulators, we assessed the 
expression of candidate genes that encode for secretory proteins with unknown 
functions. We determined which of the candidate genes whose expression is 
responsive to metabolic and nutritional cues, suggestive of involvement in 
metabolic processes. Here, we focus our functional studies on one such gene, 
Protease Associated Domain Containing 1 (Pradc1), and show that it encodes a 
novel secreted regulator of energy metabolism.  
PRADC1 (also known as PAP21) is a ~30 kDa N-glycosylated secretory 
protein with a protease associated domain (4). An ortholog encoding PRADC1 is 
found in Drosophila, worms (C. elegans), zebrafish, Xenopus, mice, and humans. 
While its evolutionary conservation across species (4) suggests a basic necessity 
for the gene, the biological function of PRADC1 remains elusive. We found that 
PRADC1 is widely expressed in both human and mouse tissues and its expression 
in metabolically active tissues is acutely regulated by fasting and refeeding while 
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being chronically altered in a diet-induced obese mouse model. Using a genetic 
loss-of-function mouse model, we demonstrated an important sex-dependent role 
for PRADC1 in modulating physical activity and adiposity in the context of obesity 
induced by high-fat feeding. Despite reduced body weight and adiposity, PRADC1-
deficient female mice fed a high-fat diet did not exhibit an improved metabolic 
profile compared to wild-type littermates. Thus, PRADC1-deficient mice appear to 
have reduced adiposity and enhanced locomotor activity uncoupled from 
metabolic health. Our mouse model establishes the biological function of PRADC1, 
providing a physiological context to further understand its mechanisms of action.          
 
 
Materials and Methods 
 
Gene expression profiling 
Gene expression profiling was performed using the TissueScanTM (OriGene) 
human major tissue qPCR array (#HMRT303) and mouse tissues from wild-type 
C57BL/6J mice. Primers used in real-time PCR analysis were: human PRADC1 
forward, 5’-CACGGCTTCCGTATCCATGAT-3’ and reverse, 5’-
GGTGAATCTGCTCATAC CTTGTG-3’; mouse Pradc1 forward, 5’-
TGAGTCCTGGGGATATTCGATAC-3’ and reverse 5’-CAGCAGGG 
ACGAGGTGAATC-3’. For human PRADC1, all expression data were normalized 





Eight-week-old C57BL/6J male mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). Mouse tissues from different brain regions were collected from 
fasted and refed experiments. For the fasted group, food was removed for 16 h 
(beginning 10 h into the light cycle), and mice were euthanized 2 h into the light 
cycle. For the refed group, mice were fasted for 16 h and refed with chow pellets 
for 3 h before being euthanized. The Pradc1 null mouse strain (Pradc1tm1(KOMP)Vlcg) 
was generated by Regeneron Pharmaceuticals (Tarrytown, New York) (1). Live 
mice were generated from Pradc1 (+/-) sperm obtained from the KOMP Repository 
(www.komp.org). Mouse Pradc1 gene is located on chromosome 6; the gene 
consists of three exons and two introns and is 4,516 bp. To generate PRADC1-
deficient mice, a total of 4,095 bp that comprise the entire coding region of the 
gene (from immediately downstream of the ATG start codon to part of the 3’UTR) 
were replaced with a targeting cassette containing a β-galactosidase reporter 
gene, LacZ, and a neomycin-resistant gene. Only the 5’ and 3’ UTRs of Pradc1 
gene remained after replacement with the cassette. This strategy ensured that 
knockout (KO) mice were completely devoid of PRADC1 protein. Genotyping 
primers for the Pradc1 wild-type (WT) allele were: forward, 5’-
TCTGGAGGTTCAGCAGGGAC-3’ and reverse, 5’-CCTGGGAGGCAGAGCT 
AGATTC-3’. The size of the amplified WT PCR product was 388 bp. Primers for 
the knockout (KO) allele were: LacZ-forward, 5’-
GGTAAACTGGCTCGGATTAGGG -3’ and LacZ-reverse, 5’-
TTGACTGTAGCGGCTGAT GTTG-3’. The size of the amplified KO PCR product 
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was 211 bp. Pradc1 KO mice were generated on a C57BL/6N genetic background. 
All mice used in this study were generated by intercrossing Pradc1 (+/-) mice to 
obtain KO and WT littermates, and at least two independent cohorts of mice were 
used per diet group. Pradc1 KO (-/-) mice and WT (+/+) littermates were housed 
together in polycarbonate cages on a 12-h light-dark photocycle with ad libitum 
access to water and food, with no more than 5 adult mice per cage. Mice were fed 
a high-fat diet (HFD; 60% kcal derived from fat, Research Diets # D12492) or a 
matched control low-fat diet (LFD; 10% kcal derived from fat, Research Diets 
#D12450B). Diet was provided at the time of weaning (at 4 wk of age). At 
termination of the study, animals were fasted for 16 h, except for the HFD-fed 
Pradc1 KO female mice, which were fasted for 2 h before euthanasia. Tissues 
were collected, snap-frozen in liquid nitrogen, and kept at −80°C until analysis. All 
animal protocols were submitted to and approved by the Institutional Animal Care 
and Use Committee of The Johns Hopkins University School of Medicine 
(protocol# MO16M431). 
 
Serum collection and Analysis 
Blood samples were collected by tail vein bleed and serum was isolated using 
Microvette CB 300 (Sarstedt, Newton, NC) per the manufacturer’s instructions. 
Serum triglyceride (TG) and cholesterol (CH) levels were measured using an 
Infinity kit (Thermo Fisher Scientific, Middletown, VA) per the manufacturer’s 
instructions. Serum non-esterified fatty acids (NEFA) were measured using a 
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NEFA-HR(2) kit (Wako Chemicals, Richmond, VA). Serum β-hydroxybutyrate 
(BHB) was measured using a LiquiColor assay (Stanbio).  
 
ELISAs 
Serum insulin and FGF21, adiponectin (EZMADP-60K), and leptin (EZML-82K) 
levels were measured using Millipore ELISA kits (MilliporeSigma, Burlington, MA). 
Serum corticosterone was obtained using the Mouse/Rat Corticosterone kit from 
ALPCO (ALPCO, Salem, NH). Serum T3, T4, and TSH levels were obtained using 
the MILLIPLEX MAP Rat Thyroid Hormone Magnetic Bead Panel (MilliporeSigma). 
For the multiplex assay, standard curves were generated for each hormone. 
Serum was diluted according to the manufacturer’s instructions. Samples and 
standards were analyzed using a Luminex 200 instrument (Luminex, Austin, TX) 
and XPonent 3.1 software (MilliporeSigma).  
 
Glucose and insulin tolerance test 
For glucose tolerance tests, food was removed for 16 h (overnight) before mice 
were intraperitoneally (i.p.) injected with a dose of 1 g of glucose/kg body weight 
diluted in 0.9% sterile filtered saline. Blood glucose was measured at 0, 15, 30, 60, 
and 120 min after glucose injection using a glucometer (NovaMax Plus, Billerica, 
MA). For insulin tolerance tests, mice were fasted for 2 h before receiving an i.p. 
injection of insulin at a dose of 0.75 U/kg body weight (low-fat diet males and 
females, high-fat diet females) or 1.5 U/kg body weight (high-fat diet males). Blood 
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glucose was measured at 0, 15, 30, 60, and 90 min after insulin injection as 
described above.  
 
Hepatic lipid extraction 
Livers were harvested from the HFD-fed Pradc1 KO female mice following a 2 h 
food removal. Tissues were collected, flash frozen in liquid nitrogen, and stored at 
-80°C. Between 50-100 mg of liver tissue was homogenized in 500 ul of ice-cold 
distilled water. A portion of the homogenate (200 μL) was collected for lipid 
extraction by mixing with 1 mL of 2:1 chloroform-methanol and centrifuged at 313 
g for 5 min at 4°C. The chloroform phase was collected and dried under vacuum. 
Samples were reconstituted in a mixture of 3:1:1 tert-butanol-MeOH-Triton X-100 
before TG and CH content was determined using Infinity kits as described above. 
Samples were normalized to mass content. 
 
Adipose tissue lipolysis 
Mice were fasted for 2 h before receiving an i.p. injection of the β3-adrenergic 
receptor agonist, CL 316243 (Santa Cruz Biotechnology) at a dose of 1 mg/kg 
body weight. Blood glucose was measured with a glucometer before and 15 
minutes post injection. Blood was collected by the tail-vein into Microvette CB 300 
capillary tubes capillary tubes before and 15 minutes post injection. Serum was 
isolated and assayed for NEFA (Wako Diagnostics, Mountain View, CA) and 




Body Composition Analysis 
Body composition analyses for fat and lean mass were performed on mice at 24 
wk of age using Echo-MRI-100 (Echo Medical Systems, Waco, TX) at The Johns 
Hopkins University School of Medicine mouse phenotyping core facility.  
 
Indirect calorimetry  
HFD-fed WT and KO female mice at 24 wk of age were assessed daily for body 
weight changes, food intake (corrected for spillage), physical activity, and whole-
body metabolic profiling in the Comprehensive Laboratory Animal Monitoring 
System (Columbus Instruments) as previously described (5). Data were collected 
for four days to confirm that mice were acclimated to the calorimetry chambers 
(indicated by stable body weights, food intake, and diurnal metabolic patterns), and 
data were analyzed from the fourth day. 
 
Histology and analysis of crown-like structures (CLS) of adipose tissue 
Gonadal (gWAT) and inguinal (iWAT) adipose tissue from WT and Pradc1-KO 
mice were fixed immediately in 10% formalin at 4°C following dissection. Fixed 
tissues were embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin at the Histology Reference Laboratory at The Johns Hopkins University 
School of Medicine. Images were captured with an Axioplan upright microscope 
with an Axiocam color CCD camera (Carl Zeiss Microscopy). To quantify the 
crown-like structures (CLS), an RGB image (1378 µm × 1091.8 μm) with a set 
scale of 1000 pixels = 1060 μm was used. CLSs were identified as clusters of 
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macrophages that had infiltrated the adipose tissue and formed ring-like structures. 
The number of CLSs was manually counted in five random fields for each section. 
Nine mice in each group were sectioned and counted.  
 
Adipocyte cell size analysis 
Adipocyte size was measured using MRI Adipocyte Tools’ macro in ImageJ 
software as previously described (6).  
 
Blood and tissue collection 
WT and Pradc1-KO mice were fasted for 2 h, anesthetized with isoflurane, and 
blood was collected through the retro-orbital plexus using capillary tubes (Fisher 
Scientific, Hampton, NH). Tissues were immediately harvested from euthanized 
mice and flash frozen in liquid nitrogen and stored at -80°C until further processing. 
 
Quantitative real-time PCR analysis 
Total RNA was isolated from tissues using TRIzol (Thermo Fisher Scientific, 
Waltham, MA) according to the manufacturer’s instructions. Samples were treated 
with DNAseI (New England Biolabs, Ipswich, MA) to remove genomic DNA 
contamination and subjected to 3M (pH 5.2) sodium acetate (Quality Biological, 
Gaithersburg, MD) precipitation to purify RNA samples. In brief, sodium acetate 
was added at 1/10 the volume of the sample followed by the addition of 2.5 
volumes of ice cold 100% ethanol and mixed thoroughly. Samples were incubated 
at -80°C overnight and then centrifuged at 12,000 x g for 20 minutes at 4°C and 
 
 119 
the supernatant was decanted. The RNA pellets were washed twice using 1 mL of 
ice cold 75% ethanol and centrifuged at 12,000 x g at 4°C. A quick spin was 
performed to remove any traces of residual ethanol in the pellet using a very fine 
pipette tip. Purified RNA was reverse transcribed using the GoScript Reverse 
transcription system (Promega, Madison, WI). Quantitative real-time PCR 
analyses were performed on a CFX Connect system (Bio-Rad Laboratories, 
Hercules, CA) using iTaq Universal SYBR Green Supermix (Bio-Rad) per the 
manufacturer’s directions. Data were normalized to 36B4 (adipose tissue), 18S 
rRNA (skeletal muscle), and β-actin (liver) and expressed as relative mRNA levels 
using the ΔΔCt method (7). All the primers used were previously published (8-10). 
 
Statistical analysis   
Comparisons between two groups of data were performed using two-tailed 
Student’s t-tests with 95% confidence intervals, and ANOVAs were used to make 
comparisons involving more than two groups. Graphpad Prism 7 software was 
used for statistical analyses and values were considered to be statistically 
significant at P <0.05. For all data, *P < 0.05, **P < 0.01, and ***P < 0.001. All data 










Expression of Pradc1 transcript in metabolically active tissues is regulated 
by the nutritional state of the animal 
Human and mouse PRADC1 protein are highly conserved (Fig. 1A), differing by 
only one amino acid in the mature protein (excluding the signal peptide). Both 
human and mouse PRADC1 were widely expressed among a variety of tissues 
(Fig. 1B, C). Expression of Pradc1 in metabolically active tissues (liver, muscle, 
adipose, and heart), as well as different brain regions (cortex and hypothalamus), 
was acutely regulated by the nutritional state. In the refed state (overnight fast 
followed by a 3 h food intake), we observed a striking suppression of Pradc1 mRNA 
in different tissues and brain regions of normal wild-type chow-fed mice (Fig. 1D). 
In the context of obesity induced by a high-fat diet, the expression of Pradc1 was 
also reduced in kidney and brown adipose tissue (BAT) relative to mice fed a 





















Loss-of-function mouse model for PRADC1      
We employed a whole-body knockout mouse model to determine the requirement 
for PRADC1 in metabolic homeostasis. The gene targeting strategy involved the 
replacement of the entire protein-coding region of PRADC1 with the β-
galactosidase (LacZ) and neomycin-resistance cassette (Fig. 2A). Our PCR 
analysis confirmed the genotype of the WT and KO mice (Fig. 2B).  As expected, 
in the KO mice, Pradc1 transcript was not detected in the adipose tissue, heart, 
muscle, or pancreas (Fig. 2C). Pradc1 KO mice of both sexes were born at the 





Figure 1. Expression and regulation of Pradc1 in various tissues under 
different physiological states. A, Sequence alignment of full-length human 
(NP_115695) and mouse (NP_001156899) PRADC1 proteins. The 
predicted signal peptide and protease associated domain are indicated. 
B, Expression of PRADC1 in human tissue panel. C, Expression of 
Pradc1 in mouse tissues (n=11). D, Real-time PCR analysis of the 
expression of Pradc1 in different tissues and brain regions from mice 
subjected to an overnight fast (fasted group; n=7) or an overnight fast 
followed by 3 h of refeeding (refed group; n=8). E, Real-time PCR 
analysis of the expression of Pradc1 in different tissues from mice fed a 
control low-fat diet (n=11) or a high-fat diet (n=11). Expression levels 
were normalized to β-actin. BAT, brown adipose tissue; gWAT, gonadal 
white adipose tissue; iWAT, inguinal white adipose tissue. Data are 




PRADC1 deficiency is dispensable for metabolic homeostasis under basal 
conditions 
When fed a control low-fat diet (LFD), WT and Pradc1 KO mice of either sex gained 
similar weight over time, had no differences in insulin sensitivity as measured by 
glucose and insulin tolerance tests, and exhibited no differences in fasting blood 
glucose or serum triglyceride, cholesterol, non-esterified free fatty acids, or β-
hydroxybutyrate (Supplemental Fig. S1 and S2). Only LFD-fed Pradc1 KO male 
mice showed increased fasting NEFA levels compared to WT mice (Supplemental 
Fig. S1G). These data indicate that PRADC1 is dispensable for glucose and lipid 
metabolism under the basal condition where mice were consuming a control LFD. 
We also observed no differences in organ weights and blood glucose levels 















Figure 2. Generation of Pradc1 knockout (KO) mice. A, Schematic 
showing the gene targeting strategy used to generate Pradc1 KO 
mice. B, PCR genotyping results showing the successful generation 
of wild-type (WT; +/+) and homozygous knockout (-/-) mice. C, The 
absence of Pradc1 mRNA in mouse tissues of KO mice was 
confirmed by real-time PCR. eWAT, epididymal white adipose 
tissue; iWAT, inguinal white adipose tissue; LacZ, β-galactosidase; 




Loss of PRADC1 reduces weight gain in KO female mice fed a high-fat diet 
by elevating physical activity and energy expenditure  
Next, we addressed whether loss of PRADC1 affects the physiologic response to 
a high-fat diet (HFD) induced obesity. In male mice fed an HFD, body weight over 
time, glucose and insulin tolerance tests, and fasting blood glucose and serum 
triglyceride, cholesterol, non-esterified free fatty acids, and ketone (β-
hydroxybutyrate) levels were not significantly different between WT and Pradc1 
KO animals (Supplemental Fig. S3 and Table 1). In striking contrast, Pradc1 KO 
female mice gained significantly less body weight over time when fed an HFD (Fig. 
3A, B and Table 1). Reduced body weight was attributed to reduced fat mass (Fig. 
3C,D) and not due to changes in lean mass (Fig. 3E). When normalized to body 
weight, Pradc1 KO female mice had a higher percentage of lean mass (Fig. 3F). 
Food intake was not significantly different between WT and Pradc1 KO female 
mice (Fig. 3G, H). Decreased adiposity seen in the Pradc1 KO mice was due to 
increased metabolic rate as measured by the rate of oxygen consumption (Fig. 
3I,J), enhanced physical activity (Fig. 3K), and enhanced energy expenditure (Fig. 
3L). These data indicate that PRADC1 deficiency impacted whole-body energy 
balance in a sex-dependent manner. Altered thyroid hormones, stress hormone, 
and FGF-21 could potentially increase physical activity and/or energy expenditure 
in Pradc1 KO female mice. However, serum T3, T4, thyroid stimulating hormone 
(TSH), corticosterone, and FGF-21 levels were not significantly different between 
WT and Pradc1 KO female mice (Supplemental Fig. S4A-E). Since Pradc1 was 
expressed in BAT and its expression was reduced in BAT in diet-induced obese 
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mice (Fig. 1), we determined whether there are any changes in uncoupling activity 
that could lead to greater energy expenditure. Increased BAT thermogenic activity 
would be reflected in increased body temperature. Measurements of body 
temperature did not reveal significant differences between genotypes 
(Supplemental Fig. S4F). The expression of Ucp-1 in BAT and iWAT was in fact 
lower in the KO mice relative to WT littermates (Supplemental Fig. S4G); thus, 
BAT activation or “browning” of iWAT is unlikely to be the mechanism responsible 
for increased energy expenditure and reduced body weight seen in the HFD-fed 























Male (45 weeks)   Female (47 weeks)   
WT  KO 
P-
Value WT KO 
P-
Value 




































































































       
 Male (38 weeks)   Female (45 weeks)   
 WT  KO 
P-
Value WT KO 
P-
Value 
High-fat diet (HFD) N = 10 N = 6  N = 9 N = 12  












































































0.001 0.2239 NA NA NA 










Table 1. Body weight, organ weight, and fed glucose levels in WT 

















Figure 3. Reduced adiposity and enhanced physical activity and energy 
expenditure in Pradc1 KO female mice fed a high-fat diet. A, Body weight 
gain over time in WT and Pradc1 KO female mice fed a high-fat diet. B, 
Representative image of WT and KO female mice at 25 weeks old. C, 
Whole-body fat mass of WT and KO female mice as determined by Echo-
MRI. D, Percent fat mass relative to body weight. E, Whole-body lean mass 
of WT and KO female mice as determined by NMR. F, Percent lean mass 
relative to body weight. G-H, Food intake during the light (G) and dark (H) 
cycle. I-J, Rate of oxygen consumption (VO2) as a measure of metabolic 
rate in WT and KO female mice during the light (I) and dark (J) cycle. K, 
Total physical activity as measured by beam breaks in WT and KO female 
mice during the light and dark cycle. L, Energy expenditure of WT and KO 
female mice during the light and dark cycle. Female mice: WT, n=9; KO, 
n=13. Mice were at 25-26 weeks of age when indirect calorimetry analyses 





Reduced body weight and adiposity in Pradc1 KO female mice did not alter 
whole-body glucose or lipid metabolism 
Given that Pradc1 KO female mice had significantly reduced body weight and 
adiposity, and an increase in physical activity and energy expenditure, we 
reasoned that they might have improved metabolic profiles. Contrary to 
expectation, insulin sensitivity as measured by glucose and insulin tolerance tests, 
as well as fasting and refed blood glucose, and serum triglyceride, cholesterol, 
non-esterified free fatty acid, and ketone (β-hydroxybutyrate) levels were not 
significantly different between HFD-fed WT and Pradc1 KO female mice (Fig. 4A-
G). Hepatic triglyceride and cholesterol levels were also not significantly different 
between WT and KO female mice (Fig. 4H,I). We also measured the circulating 
levels of two major adipocyte-derived adipokines, leptin and adiponectin. Serum 
levels of leptin and adiponectin in both the fed and fasted state were not 



























Figure 4. Glucose and lipid metabolism in WT and Pradc1 KO female mice 
fed a high-fat diet. A-B, Glucose tolerance (A) and insulin tolerance (B) 
tests in WT (n=8-9) and KO (n=13) female mice at 18 and 19 weeks of 
age. C-G, Overnight fast and refed blood glucose, serum triglyceride, 
cholesterol, non-esterified free fatty acids (NEFA), and β-hydroxybutyrate 
in WT (n=9) and KO (n=12) female mice. H-I, liver triglyceride and 
cholesterol levels in WT (n=9) and KO (n=12) female mice. J-K, Serum 
leptin and adiponectin levels in fed and overnight fasted WT (n=9) and KO 
(n=12) female mice. Animals were at 43-45 weeks of age when serum 
metabolite and adipokines were measured. Data are expressed as mean 




Impact of PRADC1 deficiency on adipose tissue histology, function, and 
gene expression in female mice 
It is known that high-fat diet induced obesity leads to adipocyte hypertrophy and 
macrophage infiltration (11-13). Since Pradc1 KO female mice had reduced 
adiposity, we therefore determined the impact of PRADC1 deficiency on adipose 
tissue structure and function. Histological analysis of visceral (gonadal) and 
subcutaneous (inguinal) fat depots between HFD-fed WT and Pradc1 KO female 
mice revealed comparable adipocyte cell size and no significant difference in the 
number of crown-like structures that marked apoptotic adipocytes surrounded by 
infiltrating macrophages (Fig. 5A-E). We next determined whether there were any 
functional differences in fat mobilization in adipose tissue between WT and KO 
mice in response to β3-adrenergic receptor agonist (CL 316243) stimulation. The 
extent of adipose tissue lipolysis, as judged by glycerol release into plasma, was 
reduced in Pradc1 KO female mice (Fig. 5F). Serum levels of non-esterified free 
fatty acids (NEFA) were not significantly different between genotypes in response 
to CL stimulation (Fig. 5G). The expression of fatty acid synthesis, triglyceride 
synthesis, and fat oxidation genes were largely unchanged in WT and Pradc1 KO 
female mice (Table 2). Seven out of the fifteen inflammation-related genes profiled 
by real-time PCR were altered between WT and KO female mice in a depot-
specific manner (Table 2). Specifically, the expression of Tnf-α, F4/80, and Il-10 
was reduced in the visceral fat depot of KO female mice relative to WT controls.  
In the subcutaneous fat depot, the expression of Tnf-α, Mcp-1, Ccl3, Ccl4, F4/80, 
and Cd68 was decreased in KO female mire compared to WT controls. Reduced 
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inflammatory gene expression in the white adipose tissue, however, did not appear 
to affect serum adipokine (adiponectin and leptin) levels, nor whole-body lipid 
profiles and glucose metabolism (Fig. 4). Genes involved in ER stress (e.g., Atf4), 
oxidative stress (e.g., Nqo1), and fibrosis (e.g., Tgf-β) were also downregulated in 
















Figure 5. Impact of PRADC1 deficiency on adipocyte size, crown-like 
structures, and adipose lipolysis in female mice fed a high-fat diet. A-B, 
Representative histology (H&E stained; 100X magnification) of visceral 
(gonadal) and subcutaneous (inguinal) white adipose tissue (WAT) of 
WT and KO female mice at 45 weeks of age. C-D, Quantification of 
adipocyte cell size in gonadal (gWAT) and inguinal (iWAT) white adipose 
tissue of WT (n=9) and KO (n=9) female mice. E, Quantification of crown-
like structures in gWAT of WT (n=9) and KO (n=9) female mice. F-G, 
Serum glycerol and non-esterified free fatty acids (NEFA) levels in 31-
week-old WT (n=9) and KO (n=13) female mice injected with a β3-
adrenergic receptor agonist (CL 316243) to induce adipose lipolysis. 











  Visceral (gonadal) WAT   Subcutaneous (inguinal) WAT 




WT KO   P-value 
Fatty acid 
synthesis N=8 N=8  N=8 N=8  
Fasn 1.00 ± 0.26 1.28 ± 0.41 0.574 1.00 ± 0.31 0.58 ± 0.19 0.3044 
Acc1 1.00 ± 0.22 0.74 ± 0.16 0.385 1.00 ± 0.16 0.89 ± 0.32 0.768 
Scd1 1.00 ± 0.16 0.92 ± 0.26 0.816 1.00 ± 0.09 0.62 ± 0.10* 0.022 
Srebp-1c 1.00 ± 0.11 1.01 ± 0.22 0.946 1.00 ± 0.34 0.54 ± 0.16 0.291 
Ppar-γ 1.00 ± 0.16 0.74 ± 0.13 0.247 1.00 ± 0.20 0.55 ± 0.19 0.146 
Triglyceride 
synthesis       
Gpat1 1.00 ± 0.11 1.08 ± 0.12 0.635 1.04 ± 0.08 0.82 ± 0.18 0.545 
Gpat2 1.00 ± 0.20 0.68 ± 0.16 0.256 N/A N/A  
Agpat1 1.00 ± 0.08 0.89 ± 0.14 0.534 1.00 ± 0.08 1.47 ± 0.38 0.260 
Agpat2 1.00 ± 0.20 1.13 ± 0.26 0.698 1.00 ± 0.22 0.41 ± 0.05* 0.046 
Dgat1 1.00 ± 0.08 0.89 ± 0.16 0.586 1.00 ± 0.15 0.71 ± 0.24 0.337 
Dgat2 1.00 ± 0.12 1.16 ± 0.26 0.560 1.00 ± 0.19 0.42 ± 0.07* 0.032 
Lipolysis       
Atgl 1.00 ± 0.17 0.91 ± 0.09 0.663 1.00 ± 0.14 0.90 ± 0.31 0.776 
Hsl 1.00 ± 0.17 0.78 ± 0.16 0.389 1.00 ± 0.13 0.72 ± 0.22 0.317 
Fat oxidation       
Ppar-α 1.00 ± 0.26 0.87 ± 0.15 0.708 1.00 ± 0.16 0.84 ± 0.31 0.672 
Cpt-1a 1.00 ± 0.12 0.75 ± 0.14 0.205 1.00 ± 0.16 0.59 ± 0.17 0.112 
Acox1 1.00 ± 0.14 0.90 ± 0.11 0.600 1.00 ± 0.19 0.72 ± 0.31 0.479 
Lcad 1.00 ± 0.08 0.69 ± 0.12 0.061 1.00 ± 0.12 0.88 ± 0.33 0.757 
Mcad 1.00 ± 0.16 0.78 ± 0.19 0.415 1.00 ± 0.13 0.89 ± 0.30 0.766 
Hadha 1.00 ± 0.11 0.58 ± 0.07* 0.010 1.00 ± 0.13 0.82 ± 0.27 0.562 
Inflammation       
Tnf-α 1.00 ± 0.11 0.58 ± 0.09* 0.013 1.00 ± 0.16 0.51 ± 0.05* 0.021 
IL-1β 1.00 ± 0.15 1.38 ± 0.40 0.397 1.00 ± 0.15 3.34 ± 1.11 0.073 
IL-6 1.00 ± 0.17 0.78 ± 0.13 0.352 1.00 ± 0.32 0.87 ± 0.23 0.767 
Mcp-1 1.00 ± 0.15 1.11 ± 0.28 0.719 1.00 ± 0.12 0.55 ± 0.05** 0.005 
Ccr2 1.00 ± 0.12 1.16 ± 0.27 0.598 1.00 ± 0.13 1.00 ± 0.20 0.980 
Ccl3 1.00 ± 0.12 0.65 ± 0.12 0.072 1.00 ± 0.12 0.37 ± 0.03*** 0.001 
Ccl4 1.00 ± 0.10 0.92 ± 0.14 0.687 1.00 ± 0.16 0.51 ± 0.05* 0.021 
Nos2 1.00 ± 0.23 1.19 ± 0.33 0.647 1.00 ± 0.15 0.81 ± 0.26 0.550 
F4/80 1.00 ± 0.11 0.62 ± 0.08* 0.025 1.00 ± 0.09 0.55 ± 0.07** 0.002 



















Cd206 1.00 ± 0.17 1.57 ± 0.35 0.171 1.00 ± 0.14 0.62 ± 0.11 0.055 
IL-10 1.00 ± 0.07 0.63 ± 0.11* 0.019 1.00 ± 0.11 1.18 ± 0.24 0.491 
Arg1 1.00 ± 0.22 0.82 ± 0.17 0.556 1.00 ± 0.13 0.85 ± 0.24 0.646 
Cd68 1.00 ± 0.12 0.66 ± 0.13 0.100 1.00 ± 0.16 0.46 ± 0.11* 0.016 
Retnl 1.00 ± 0.44 1.70 ± 0.46 0.295 1.00 ± 0.13 1.21 ± 0.41 0.641 
Fibrosis       
Tgf-β 1.00 ± 0.13 0.44 ± 0.08** 0.004 1.00 ± 0.14 0.58 ± 0.16 0.081 
Col3a1 1.00 ± 0.19 0.80 ± 0.14 0.4414 1.00 ± 0.16 0.60 ± 0.17 0.112 
Col6a1 1.00 ± 0.10 0.99 ± 0.11 0.988 1.00 ± 0.10 0.78 ± 0.20 0.391 
Hif-1α 1.00 ± 0.08 1.04 ± 0.11 0.763 1.00 ± 0.24 0.81 ± 0.27 0.617 
ER stress       
Xbp-1s 1.00 ± 0.08 0.83 ± 0.13 0.329 1.00 ± 0.13 0.74 ± 0.13 0.201 
Xbp-1t 1.00 ± 0.07 0.81 ± 0.08 0.115 1.00 ± 0.07 0.90 ± 0.07 0.393 
Chop 1.00 ± 0.05 0.87 ± 0.07 0.212 1.00 ± 0.18 0.59 ± 0.13 0.098 
Atf4 1.00 ± 0.06 0.78 ± 0.06* 0.037 1.00 ± 0.06 0.81 ± 0.10 0.167 
Oxidative 
stress       
Sod1 1.00 ± 0.14 0.97 ± 0.12 0.892 1.00 ± 0.08 0.94 ± 0.11 0.740 
Sod2 1.00 ± 0.10 1.06 ± 0.12 0.713 1.00 ± 0.15 0.80 ± 0.18 0.468 
Cox2 1.00 ± 0.21 1.05 ± 0.24 0.860 1.00 ± 0.18 0.86 ± 0.22 0.636 
Nox4 1.00 ± 0.12 0.94 ± 0.10 0.762 1.00 ± 0.11 0.87 ± 0.16 0.539 
Nqo1 1.00 ± 0.21 0.50 ± 0.13 0.077 1.00 ± 0.10 0.51 ± 0.05** 0.001 
Table 2. Real-time PCR analysis of the expression of metabolic, 
inflammatory, and oxidative stress genes in visceral and 
subcutaneous fat depots of WT and Pradc1 KO female mice fed a 






PRADC1, as a novel metabolic regulator and secretory protein, is significantly 
suppressed in metabolically active tissues (liver, adipose, skeletal muscle, kidney, 
and heart), as well as in different brain regions (hypothalamus and cortex) during 
the refeeding phase following an overnight fast. The striking nutritional regulation 
of Pradc1 expression suggests a metabolic function for this protein. We used a 
genetic loss-of-function mouse model to determine if PRADC1 is required for 
maintaining energy homeostasis.  
 
Under non-stressed basal conditions when mice were fed a control low-fat diet, 
PRADC1 was dispensable for metabolic control. None of the major metabolic 
parameters—body weight, insulin sensitivity, fasting glucose, or serum lipid 
profiles—were significantly different between genotypes of either sex. However, 
significant sex-dependent phenotypes were revealed when Pradc1 KO mice were 
challenged with a high-fat diet to induce obesity and metabolic dysfunction, 
underscoring the importance of sex as a significant biological variable in the 
physiologic response to high caloric intake (14-16). Obese male Pradc1 KO mice 
consuming a high-fat diet appeared indistinguishable from WT littermates in whole-
body glucose and lipid metabolism. In striking contrast, female Pradc1 KO mice 
gained significantly less body weight and fat mass relative to WT littermates when 
fed a high-fat diet. Reduced adiposity is not due to any differences in food intake; 
rather, we attribute it, at least in part, to increased physical activity and energy 
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expenditure in Pradc1 KO animals. We ruled out changes in thyroid or stress 
hormones, or circulating FGF-21 levels, as the possible cause of elevated physical 
activity and energy expenditure; none of these were significantly different between 
genotypes. Increased BAT thermogenic activity could result in greater energy 
dissipation; however, the body temperature was not significantly different between 
genotypes. Expression of Ucp1 was, in fact, lower in BAT and iWAT of Pradc1 KO 
mice compared to WT controls, thus ruling out uncoupling or “browning” of iWAT 
as a possible contributor to increased energy expenditure and lower adiposity seen 
in the KO animals. Sympathetic input via the adrenergic pathway can promote 
lipolysis in WAT and BAT, as well as BAT activation (17,18). Loss of PRADC1 
could potentially lead to greater lipid turnover in adipose tissue. In fact, we 
observed reduced lipolysis in Pradc1 KO female mice in response to a β3-
adrenergic receptor agonist (CL 316243) stimulation compared to WT controls.  
Thus, our data point to increased physical activity as a likely contributor to 
increased energy expenditure in Pradc1 KO female mice fed a high-fat diet.   
 
Excess adiposity is tightly linked to metabolic dysfunction (19). In the obese state, 
adipose tissue undergoes significant remodeling that impairs its functions; these 
include low-grade inflammation due to immune cells infiltration (11-13) and fibrosis 
(20). Due to elevated physical activity and marked reduction in body weight (~15%) 
between genotypes, we expected to see significant improvements in glucose and 
lipid metabolism in the female Pradc1 KO mice relative to WT littermates. 
Surprisingly, the metabolic profiles—insulin sensitivity, fasting blood glucose and 
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serum lipid profiles, extent of hepatic steatosis, and adipose tissue inflammation—
were largely indistinguishable between WT and Pradc1 KO female mice. It appears 
that in this mouse model, physical activity and adiposity are uncoupled from 
metabolic health, and that enhanced locomotor activity and reduced fat mass are 
insufficient to improve local inflammatory milieu within the adipose tissue, as well 
as systemic glucose and lipid metabolism in the context of an obesogenic diet. The 
integrative nature of energy balance and whole-body metabolism entails complex 
regulatory mechanisms that remain poorly understood. While elevated physical 
activity generally confers significant health benefits in humans and animal models 
(21), there are subsets of humans where regular exercise appears to have only 
limited improvements in metabolic health (22). Increased adiposity due to obesity 
is known to be a major risk and contributing factor to impaired insulin action and 
metabolic health (19); conversely, reducing fat mass through exercise or surgical 
interventions often significantly improves insulin sensitivity and systemic glucose 
and lipid profiles (23-25). Thus, the uncoupling of physical activity and fat mass 
from systemic metabolic health seen in the Pradc1 KO female mice sheds lights 
on the complex regulation of energy balance.   
 
In summary, our effort to identity novel metabolically responsive secretory proteins 
led to the functional characterization of PRADC1. Future studies will help address 
whether the combination of phenotypes we observed in KO female mice are 
primarily due to the lack of PRADC1’s action in peripheral tissues and/or brain 
where it is expressed. In light of how little is known about this evolutionarily 
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conserved protein, our studies lay the groundwork and provide a context to further 





































Supplemental Figure S1. Metabolic parameters of WT and Pradc1 KO 
male mice fed a control low-fat diet. A, Body weight gain over time in 
WT (n=16) and KO (n=13) male mice. B-C, Glucose tolerance (B) and 
insulin tolerance (C) tests in WT (n=14) and KO (n=12) male mice at 18 
and 19 weeks of age. D-H, Overnight fasting blood glucose, serum 
triglyceride, cholesterol, non-esterified free fatty acids (NEFA), and β-
hydroxybutyrate in 17-week-old WT (n=16) and KO (n=13) male mice. 












Supplemental Figure S2. Metabolic parameters of WT and Pradc1 KO 
female mice fed a control low-fat diet. A, Body weight gain over time in 
WT (n=19) and KO (n=16) female mice. B-C, Glucose tolerance (B) and 
insulin tolerance (C) tests in WT (n=14 or 15) and KO (n=13) female mice 
at 18 and 19 weeks of age. D-G, Overnight fasting blood glucose, serum 
triglyceride, cholesterol, non-esterified free fatty acids (NEFA), and β-
hydroxybutyrate in 17- week-old WT (n=19) and KO (n=16) female mice. 











Supplemental Figure S3. Metabolic parameters of WT and Pradc1 KO 
male mice fed a high-fat diet. A, Body weight gain over time in WT (n=13) 
and KO (n=7) male mice. B-C, Glucose tolerance (B) and insulin tolerance 
(C) tests in WT (n=13) and KO (n=7) male mice at 18 and 20 weeks of age. 
D-H, Overnight fasting blood glucose, serum triglyceride, cholesterol, non-
esterified free fatty acids (NEFA), and β-hydroxybutyrate in 17-week-old WT 









Supplemental Figure S4. Serum levels of thyroid hormones, 
corticosterone, FGF-21, and body temperature of WT and Pradc1 KO 
female mice fed a high-fat diet. A-E, Serum T3, T4, thyroid stimulating 
hormone (TSH), corticosterone, and FGF-21 levels in 40-week-old WT 
(n=9-11) and KO (n=12) female mice. F, Body temperature of WT and KO 
female mice as measured by a rectal probe (Physitemp; model BAT-12). 
G, Real-time PCR analysis of Ucp-1 expression in inguinal white adipose 
tissue (iWAT) and interscapular brown adipose tissue (BAT) of WT and 
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